

Curriculum vitae

Date Prepared: September 9, 2022
Name: Heather Lynn McArthur
Office Address: 5323 Harry Hines Blvd, Dallas TX 75390-8845
Cell Phone: 213-321-2251
Work Phone: 214-648-5311
Work Fax: 214-645-6367
Work E-Mail: Heather.McArthur@UTSouthwestern.edu
Place of Birth: Canada

Education

Year(s)	Degree	Field of Study	Institution
1/1995 – 5/1997	BSc. Hons.		University of British Columbia
8/1997 – 6/2001	M.D.	Medicine	University of Toronto
7/2006 – 8/2008	MPH		Harvard University

Postdoctoral Training

Year(s)	Titles	Specialty/Discipline	Institution
7/2001 – 6/2004	Intern/Resident	Internal Medicine	University of Calgary
7/2004 – 6/2005	Fellow	Medical Oncology	British Columbia Cancer Agency (BCCA) University of British Columbia
7/2005 – 1/2006	Chief Fellow	Medical Oncology	British Columbia Cancer Agency (BCCA) University of British Columbia
7/2006 – 2/2010	Advanced Clinical Breast Cancer Research Fellow	Breast Cancer Medicine Service	Memorial Sloan Kettering Cancer Center (MSKCC)

Current Licensure and Certification

2015 – 2017 State of New York – Medical Licensure
2016 – 2022 State of California – Medical Licensure

Board and Other Certification

Certification, Internal Medicine, Royal College of Physicians and Surgeons of Canada, 2005
Certification, Medical Oncology, Royal College of Physicians and Surgeons of Canada, 2006
Certification, U.S. Medical Licensing Exam (USMLE) – Steps 1, 2, and 3, 2006

Honors and Awards

Year	Name of Honor/Award	Awarding Organization
1997	Edgar C. Black Memorial Prize for Outstanding Honors Student	Department of Physiology, University of British Columbia
1998	Certificate awarded in Recognition for Dedication to Community Affairs	Faculty of Medicine, University of Toronto
1999	Certificate of Appreciation	Office of Student Affairs, Faculty of Medicine, University of Toronto
1999	Certificate of Appreciation in Recognition of Leadership in the Saturday Tutorial Program	Toronto District School Board
2003	Award for Excellence in Teaching in the Clinical Clerkship Undergraduate Medical Education Program	University of Calgary
2004	Award for Excellence in Research [Second Place]	Canadian Society of Internal Medicine
2005	First Prize, Poster Award for Translation II – Adoption	British Columbia Cancer Agency Annual Cancer Conference
2006	Stefan Grzbowski Prize for Best Research Project by a Fellow	University of British Columbia (UBC) Department of Medicine
2006	First Prize, Poster Award for Epidemiology and Population Research	BCCA Annual Cancer Conference
2007	Foundation Merit Award	American Society of Clinical Oncology (ASCO)
2008	AstraZeneca Clinical Scholars Award	San Antonio Breast Cancer Symposium
2009	Cancer Foundation Merit Award	ASCO
2015	Eileen Dreyer Memorial Lecture Award	SASS Foundation for Medical Research Inc.
2018	LA Goes Pink Award in Tribute to Liz Smagala Tate	Breast Cancer Research Foundation (BCRF)
2018	Chiles Visiting Professor	Earle A. Chiles Research Institute
2019	Laura Ziskin Prize In Translational Cancer Research	Stand Up To Cancer (SU2C)
2019	ASCO Advocacy Program, Senator's Club Level	ASCO
2019	LA Goes Pink Award in Tribute to Liz Smagala Tate	BCRF
2020	Robert L. Longmire Lectureship	Scripps MD Anderson Cancer Center
2020	Nominee, "Woman Oncologist of the Year"	Women Leaders in Oncology
2020	LA Goes Pink Award in Tribute to Liz Smagala Tate	BCRF

2020	LA's Top Doctors	Los Angeles Magazine
2020 - 2021	Certificate of Excellence (Recognition of being in the top 10% nationally in patient experience performance of all physicians in specialty)	Cedars-Sinai Medical Center
2021	Bernard Lee Schwartz Cancer Lectureship	Scripps MD Anderson Cancer Center

Faculty Academic Appointments

Year(s)	Academic Title	Department	Academic Institution
2010 – 2013	Instructor	Department of Medicine	Joan & Sanford Weill Medical College of Cornell University Medical College
2014 – 2016	Assistant Professor	Department of Medicine	Joan & Sanford Weill Medical College of Cornell University Medical College
2018 – 2021	Associate Professor	Department of Medicine	Cedars Sinai Medical Center (CSMC)
2020 – 2021	Health Science Clinical Professor in Residence	Department of Medicine	David Geffen School of Medicine at UCLA
2021 – present	Associate Professor	Department of Medicine	UT Southwestern Medical Center

Appointments at Hospitals/Affiliated Institutions

<u>Past</u>			
Year(s)	Position Title	Department/Division	Institution
2010 – 2013	Assistant Attending Physician, Level 1	Department of Medicine	Memorial Sloan Kettering Cancer Center (MSKCC)
2013 – 2016	Assistant Attending Physician	Department of Medicine	Memorial Sloan Kettering Cancer Center (MSKCC)
2016 – 2021	Staff Physician	Department of Medicine	Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
<u>Current</u>			
Year(s)	Position Title	Department/Division	Institution
2021 - present	Staff Physician	Department of Medicine	UT Southwestern Medical Center

Major Administrative/Leadership Positions

Year(s)	Position Title	Institution
---------	----------------	-------------

2016 – 2021	Medical Director, Breast Oncology	Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
2021 – present	Komen Distinguished Chair in Clinical Breast Cancer Research	UT Southwestern Medical Center
2021 – present	Clinical Director, Breast Cancer Program	UT Southwestern Medical Center

Committee Service (*Member, unless noted otherwise*)

Year(s)	Name of Committee	Institution/Organization
<u>UTSW</u>		
2021 – present	Breast Care Executive Committee	UT Southwestern Medical Center
2021	Interviewer, Hematology/Oncology Fellowship Program	UT Southwestern Medical Center
2021 – present	Clinical Services Transition Committee	UT Southwestern Medical Center
2021 – present	Feasibility Committee	UT Southwestern Medical Center
2021 – present	Gurbakhash Kaur Mentoring Committee	UT Southwestern Medical Center
2021 – present	Tanner Reese PhD Thesis Committee	UT Southwestern Medical Center
2022 – present	Administrative/Staff Operations Working Group	UT Southwestern Medical Center
<u>Memorial Sloan Kettering Cancer Center</u>		
2010-2016	Reviewer, Departmental QA Committee	MSKCC
2010-2016	Interviewer, Medical Oncology Fellowship Program	MSKCC
2010-2016	Interviewer, junior faculty recruitment	MSKCC
2010-2016	Medicine Steering Committee Panelist, Career Options: Advice for Residents and Fellows	MSKCC
2010-2016	Panelist, Women’s Research Seminar, “Spotlight on Current Research”	MSKCC
<u>Cedars-Sinai Medical Center</u>		
2017 – 2018	Cancer Director Search Committee	Cedars-Sinai Medical Center
2017 – 2018	Co-Chair, End-of-Life Task Force	Cedars-Sinai Medical Center
2018	Panelist, Women’s Research Seminar, “Spotlight on Current Research”	Cedars-Sinai Medical Center
2017 – 2019	Chair, Breast Oncology DRG/Clinical Algorithm Committee	Cedars-Sinai Medical Center
2017 – 2020	Survivorship Committee	Cedars-Sinai Medical Center
2017 – 2020	Cancer Quality Committee	Cedars-Sinai Medical Center
2017 – 2020	Cancer Committee	Cedars-Sinai Medical Center
2017 – 2021	Reviewer, Internal Grant Program	Cedars-Sinai Medical Center
2017 – 2021	Interviewer, Internal Medicine Residency Program	Cedars-Sinai Medical Center
2018 – 2019	Cardiology Chair Search Committee	Cedars-Sinai Medical Center

2019 – 2020	Gynecology-Oncology Division Director Search Committee	Cedars-Sinai Medical Center
2020	Melanoma Scientist Search Committee	Cedars-Sinai Medical Center
<u>State/Regional</u>		
None		
<u>National/International</u>		
2012	Breast Cancer Steering Committee, Clinical Trials Planning for the Next Generation Trails for ER+ Breast Cancer	National Cancer Institute (NCI)
2012	Chair, Breast Cancer Symposium General Session	ASCO
2012 – 2014	Conquer Cancer Foundation YIA/CDA Grants Selection Committee	ASCO
2012 – 2014	Breast Cancer Symposium Program Committee	ASCO
2015 – 2017	ASCO Grant Writing Workshop Planning Group	ASCO
2016	US Co-Chair, Breast International Group (BIG) Immunotherapy Taskforce	Breast International Group (BIG)
2016 – 2017	Alliance for Clinical Trials in Oncology Immunotherapy/Immune Monitoring Working Group	Alliance
2016 – 2018	Breast Cancer Steering Committee Immuno-Oncology Working Group	National Cancer Institute (NCI)
2017	ASCO Guideline Expert Panel on American Society for Radiation Oncology (ASTRO) Whole Breast Irradiation Guideline	ASCO
2017 – present	Breast Committee	Southwest Oncology Group (SWOG)
2017 – present	ASCO Educational Book Expert Panel	ASCO
2018	Co-Chair, ASCO Clinical Science Symposium – Breast Cancer Immunotherapy: Can We Crack the Code?	ASCO
2018 – 2020	ASCO Scientific Program Committee-Developmental Therapeutics & Translational Research – Immunology	ASCO
2018 – 2019	Alliance for Clinical Trials in Oncology Immuno-Oncology Committee	Alliance
2018 – present	NCI Breast Cancer Steering Committee Breast Immuno-Oncology Task Force	National Cancer Institute (NCI)
2019	Co-Chair, ASCO Annual Meeting Developmental Immunotherapy and Tumor Immunobiology Session	ASCO
2019	ASCO value framework benchmark study, Invited Participant	ASCO

2019 – present	ASCO Expert Guideline Panel on Chemo and Targeted Therapy for Women with HER2 Negative (or unknown) Advanced Breast Cancer	ASCO
2019 – present	Alliance for Clinical Trials in Oncology Immuno-Oncology Committee Advisory Council	Alliance
2019 – 2020	ASCO Scientific Program Committee, Developmental Immunotherapy and Tumor Immunobiology, Track Leader	ASCO
2019 – 2020	ASCO Annual Meeting Education Committee	ASCO
2020 – present	Oncology Education Scientific Steering Committee	Oncology Education
2020 – 2021	Advanced Clinical Research Award (ACRA) in Immune Checkpoint Inhibitor Therapy Review Committee	ASCO
2020 – 2021	Society for Immunotherapy of Cancer (SITC) Breast Cancer Immunotherapy Guidelines (CIG) Breast Cancer Expert Panel	SITC
2020 – present	The State of Cancer Care in America (SOCCA) Practice Health Writing Group	ASCO
2020	Co-Chair, Latin America Virtual Preceptorship Program on Breast Cancer Management	OncInfo
2021 – present	Diversity in Clinical Trials Career Development Program	Bristol Myers Squibb in collaboration with the American Association for Cancer Research (AACR) and the National Medical Fellowships (NMF)
2021 – present	ASCO Clinical Practice Committee	ASCO
2021 – present	AstraZeneca Breast Cancer Steering Committee	AstraZeneca
2021 – present	Co-Chair, Practice Health Task Force	ASCO
2021 – present	Alliance for Clinical Trials Breast Committee	Alliance
2021 – present	Alliance for Clinical Trials Data Safety Monitoring Board (DSMB)	Alliance
2021 – present	Alliance for Clinical Trials IO Committee	Alliance
2021 – present	Bio IO Task Force	National Cancer Institute
2021 – present	CAPitello-290 Investigator Steering Committee	AstraZeneca

Professional Societies

Dates	<u>Society, member</u>
2005 – present	American Society of Clinical Oncology (ASCO)
2006 – present	American Association for Cancer Research (AACR)
2010 – present	Alliance for Clinical Trials (previously CALGB)

2013 – present	Society of Immunotherapy of Cancer (SITC)
2016 – present	European Society for Medical Oncology (ESMO)
2017 – present	Southwest Oncology Group (SWOG)
2018	Breast Cancer Research Foundation/ Cancer Research Institute/Parker Institute for Cancer Immunotherapy Think Tank
2018 - 2019	ASCO Leadership Development Program
2018 - 2021	CANCER Editorial Advisory Board
2019	Congressionally Directed Medical Research Programs (CDMRP) Breast Cancer Research Program (BCRP), Reviewer
2019 - present	International Immuno-Oncology Biomarker/TILs Working Group
2019 - present	Editorial Board, Breast Cancer Research and Treatment
2020 - present	Associate Editor, Clinical Research, Breast Cancer Research
2020	New Data, New Opportunities, and New Clinical Challenges Using Immunotherapies for Triple-Negative Breast Cancer, CME program, Program Director
2021 – present	Practice Health Task Force, Co-Chair
	<u>Invited Manuscript Reviews</u>
2007	Drug Safety
2008	Cancer Chemotherapy and Pharmacology
2008 – 2010, 2012, 2018	Journal of Clinical Oncology
2008	Pharmacoepidemiology and Drug Safety
2008, 2009, 2018, 2019	Cancer
2008 – 2010, 2018, 2020	Clinical Breast Cancer
2008, 2011	Oncology
2009	Drug Profiles
2009 – 2010	Biomarkers
2009, 2015	Clinical Advances in Hematology & Oncology
2009	Clinical Cancer Research
2009 – 2011	Nature Reviews Clinical Oncology
2010	Journal of Surgical Oncology
2011	Proteome Science
2012, 2018	International Journal of Breast Cancer
2012, 2014	Cancer Treatment Reviews
2013	American Journal of Clinical Oncology
2014, 2015, 2018, 2022	New England Journal of Medicine
2014, 2019	Annals of Oncology
2014	Cancer Immunology Research

2016	Science
2016, 2018, 2019, 2021	NPJ Breast Cancer
2017	Journal of Targeted Therapies in Cancer
2017, 2018	Journal of the National Comprehensive Cancer Network
2018	Therapeutic Advances in Medical Oncology
2018	Journal of Oncology Practice
2018	Annals of Translational Medicine
2018, 2020	JAMA Oncology
2019	Nature Scientific Reports
2019 – 2021	Breast Cancer Research and Treatment
2019	F1000 Research
2020, 2021	Breast Cancer Research
2020, 2021	Journal for ImmunoTherapy of Cancer

Grant Support

<u>Present</u>	Grantor: ASCO Advanced Clinical Research Award in Breast Cancer
	Title of Project: A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard peri-operative care in women with hormone receptor-negative, HER2-negative early stage/resectable breast cancer.
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$150,000 07/01-06/30
	Total amount of award (if multi-year) and dates (direct costs only): \$450,000 07/01/19-06/30/22
<u>Present</u>	Grantor: Stand Up to Cancer (SU2C) Catalyst Research Grants (Genentech-Supported Project Mechanism)
	Title of Project: Combination ipatasertib and atezolizumab to prevent recurrence in TNBC
	Role: Partnering PI (PI: Elizabeth Mittendorf, Dana-Farber Cancer Institute)
	Annual amount and date (direct costs only): \$999,975 04/01-03/31
	Total amount of award (if multi-year) and dates (direct costs only): \$2,999,925 04/01/19-03/31/22
<u>Present</u>	Grantor: Department of Defense, Breast Cancer Research Program (BCRP) Breakthrough Award - Funding Level 3 - Clinical Trial - Partnering PI Option
	Title of Project: A five-year grant shared by multiple scientists at different institutions to collaborate on high-risk, high-reward breast cancer research focused on getting new treatments to patients quickly.
	Role: Partnering PI (Lead PI: Silvia Formenti, MD)

	Annual amount and date (direct costs only): \$666,666 2/20-06/30
	Total amount of award (if multi-year) and dates (direct costs only): \$4,000,000 09/01/18-09/30/24
<u>Present</u>	Grantor: Susan G. Komen, Career Catalyst Research Basic/Translational and Clinical
	Title of Project: Ipilimumab, nivolumab and cryoablation in women with resectable breast cancer.
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$112,500 02/20-06/30
	Total amount of award (if multi-year) and dates (direct costs only): \$450,000 02/20/17-06/30/21 (NCE pending)
<u>Present</u>	Grantor: Breast Cancer Research Foundation (BCRF)
	Title of Project: Predicting clinical outcome to Her2-targeted therapy from histopathology deep learning
	Role: Co-PI (co-PI: Dan Ruderman)
	Annual amount and date (direct costs only): \$175,000 10/1/20-9/30/21
<u>Present</u>	Grantor: Breast Cancer Research Foundation (BCRF)
	Title of Project: Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab (neoHIP)
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$175,000 10/1/20-9/30/21
<u>Deferred</u>	Grantor: Breast Cancer Research Foundation (BCRF)
	Title of Project: A pilot study of brain irradiation with or without tremelimumab in women with hormone receptor positive (HR+) and/or HER2-positive (HER2+) breast cancer brain metastases.
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$240,000 Deferred
<u>Past</u>	Grantor: Canadian Association of Medical Oncologists (CAMO)/Canadian Institute for Health Research (CIHR) Rx&D Research Fellowship
	Title of Project: A phase II, open-label study of the clinical activity, safety, and tolerability of lapatinib in combination with bevacizumab in subjects with advanced or metastatic erbb2 overexpressing breast cancer.
	Role: Co-I (PI: Dickler)
	Annual amount and date (direct costs only): \$64,500 07/01-06/30
	Total amount of award (if multi-year) and dates (direct costs only): \$129,000 (100% salary support for Dr. McArthur) 07/01/06-06/30/08
<u>Past</u>	Grantor: Geoffrey Beene Cancer Research Center Grant
	Title of Project:

	Use of array CGH to improve HER2 testing and better identify trastuzumab sensitivity in breast cancer
	Role: Co-PI (PI: Hudis)
	Annual amount and date (direct costs only): \$174,270 09/01-07/31
	Total amount of award (if multi-year) and dates (direct costs only): \$522,810 09/01/08-07/31/10
<u>Past</u>	Grantor: MSKCC Translational and Integrative Medicine Research Fund (TIMRF)
	Title of Project: A pilot study of pre-operative, single-dose ipilimumab and/or cryoablation in early stage/resectable breast cancer.
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$75,000 4/2013-3/2014
<u>Past</u>	Grantor: BCRF
	Title of Project: A pilot study of brain irradiation with or without tremelimumab in women with Hormonereceptor positive (HR+) and/or HER2-positive (HER2+) breast cancer brain metastases.
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$240,000 10/01/13-09/30/14
<u>Past</u>	Grantor: MSKCC TIMRF
	Title of Project: A pilot study of brain irradiation with or without tremelimumab in women with Hormone receptor positive (HR+) and/or HER2-positive (HER2+) breast cancer brain metastases.
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$100,000 04/01/14-12/31/15
<u>Past</u>	Grantor: Cedars-Sinai 2018 Translational Pipeline Discovery Fund Award
	Title of Project: Nano immunology approach for the treatment of HER2+ primary and metastatic brain tumors: importance of local immune activation.
	Role: Co-PI (co-PI: Julia Ljubimova, MD, PhD)
	Annual amount and date (direct costs only): \$80,000 06/01/18-05/31/19
<u>Past</u>	Grantor: Breast Cancer Research Foundation (BCRF)
	Title of Project: Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab

	(neoHIP)
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$250,000 10/01/19-09/30/20
<u>Past</u>	Grantor: Breast Cancer Research Foundation (BCRF)
	Title of Project: Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab (neoHIP)
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$250,000 10/01/19-09/30/20
<u>Past</u>	Grantor: Breast Cancer Research Foundation (BCRF)
	Title of Project: Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab (neoHIP)
	Role: Principal Investigator
	Annual amount and date (direct costs only): \$300,000 10/01/18-09/30/19
<u>Past</u>	Grantor: SU2C Laura Ziskin Prize In Translational Cancer Research
	Title of Project: A one-year prize shared by two scientists at two different institutions to collaborate on high-risk, high-reward breast cancer research focused on getting new treatments to patients quickly.
	Role: Co-PI (co-PI: Silvia Formenti, MD)
	Annual amount and date (direct costs only): \$250,000 (\$125,000 per co-PI) 01/21/19-01/31/21

Clinical Trials Activities (selected)

<u>Present</u>	
2017 - present	Grantor: Genentech-Roche, Breast International Group, Alliance Foundation Trials
	Title of Project: ALEXANDRA/Impassion030: A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with standard adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer
	Role: Alliance Foundation Trials Study PI, Study Co-chair, and Steering Committee Member
2017 - present	Grantor: Merck & Co.
	Title of Project:

	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)
	Role: Global Steering Committee Member
2018 - present	Grantor: Polyphor
	Title of Project: POL6326-009: A phase 3 study of balixafortide and eribulin in heavily pre-treated metastatic breast cancer
	Role: Global Steering Committee Member
2018 - present	Grantor: Merck & Co.
	Title of Project: KEYNOTE-756: A randomized, double-blind, phase 3 study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2- breast cancer
	Role: Global Steering Committee Member
2018 - present	Grantor: Eli Lilly
	Title of Project: I3Y-MC-JPCF: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone receptor positive, human epidermal receptor 2 negative, breast cancer (monarchE)
	Role: US Steering Committee Member
2019 - present	Grantor: Bristol-Myers Squibb
	Title of Project: A randomized, multicenter, double-blind, placebo-controlled phase 3 study of nivolumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy in the treatment of high-risk, stage II-III estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2) breast cancer (CA209-7FL)
	Role: Global Steering Committee Member
2019 - present	Grantor: AstraZeneca
	Title of Project: A Phase III Double-blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer (TNBC)
	Role: Global Steering Committee Member

<u>Past</u>	Grantor: Nektar Therapeutics
2019 - 2020	Title of Project: A Phase 2/3, Randomized, Open-Label Study of NKTR-214 in Combination with Nivolumab and Treatment of Physician's Choice (TPC) versus TPC in Patients with Advanced PD-L1 Negative Triple Negative Breast Cancer Sponsor: Nektar Therapeutics
	Role (Principal Investigator, Co-Investigator): Global Steering Committee Member

Teaching Activities

Year(s)	Activity
<u>Clinical Teaching</u>	
2010 – 2016	Outpatient Clinic Attending (MSKCC): Care of outpatients with body early-stage and metastatic breast cancer, managing chemotherapy, endocrine therapy, and targeted therapies. 2 clinic days/week
2010 – 2016	Inpatient Rounds Attending (MSKCC): Care of breast cancer patients who require hospitalizations to manage complications of breast cancer or its therapy. 1 month/year
2017 – 2021	Outpatient Clinic Attending (Cedars-Sinai): Care of outpatients with body early-stage and metastatic breast cancer, managing chemotherapy, endocrine therapy, and targeted therapies. 2 clinic days/week
2018 - 2021	Inpatient Rounds Attending (Cedars-Sinai): Care of breast cancer patients who require hospitalizations to manage complications of breast cancer or its therapy. 1-2 weeks/year
<u>Non-Clinical Teaching</u>	
2009	Lecturer, MSKCC Hematology-Oncology Grand Rounds, “Breast ASCO 2009 Highlights”
2009	Lecturer, MSKCC Integrative Medicine Educational Program, “Breast Cancer: An overview”
2010	Lecturer, MSKCC Hematology-Oncology Grand Rounds, “Breast ASCO 2010 Highlights”
2010	Lecturer, MSKCC Medical Oncology Fellowship Program, “Matastatic Breast Cancer: Focus on Her2 Positive Disease”
2011	Lecturer, MSKCC Hematology-Oncology Grand Rounds, “SABCS 2010 Highlights”
2011	Lecturer, MSKCC Hematology-Oncology Grand Rounds, “SABCS 2011 Highlights”
2011	Lecturer, MSKCC Integrative Medicine Educational Program, “Understanding Metastatic Disease: A Breast Oncologist’s Perspective”
2012	Lecturer, MSKCC Hematology-Oncology Grand Rounds, “A Novel Immunotherapeutic Approach to Breast Cancer”
2012	Lecturer, MSKCC Medicine House Staff Curriculum, “Approach to Breast Cancer”
2013	Lecturer, MSKCC Medicine House Staff Curriculum, “Approach to Breast Cancer”

2013	Lecturer, MSKCC Breast Disease Management Retreat, “Experimental Pre-operative Therapy”	
2014	Introduction to Medicine Clerkship Case Leader, Weill Cornell Medical College	
2014	Problem Based Learning Facilitator and Examiner, Human Structure and Function Course, Weill Cornell Medical College	
2015	Lecturer, MSKCC Breast Disease Management Retreat, “Immunomodulation and Ablation”	
2015	Lecturer, MSKCC Radiation Oncology Grand Rounds, “The Emerging Role of Immune Therapy in Breast Cancer	
2017	Lecturer, CMSC Oncology Fellowship Lecture Series, “Peri-operative Chemotherapy Issues in Breast Cancer”	
2018	Lecturer, CMSC Oncology Fellowship Lecture Series, “Approach to Triple-Negative Breast Cancer”	
2019	Lecturer, CMSC Oncology Fellowship Lecture Series, “Treatment of Triple-Negative Breast Cancer	
2020	Lecturer, CMSC Oncology Fellowship Lecture Series, “Triple Negative Breast Cancer”	
2020	Lecturer, CMSC Oncology Fellowship Lecture Series, “Curative Intent Treatment of Triple Negative Breast Cancer”	
2018 – 2021	Facilitator, CSMC Hematology Oncology Fellows Journal Club	
2020	Lecturer, Cedars-Sinai Health System Breast Oncology Retreat, “Neoadjuvant therapy updates”	
2020	Lecturer, Torrance Memorial Tumor Board, “Updates in systemic therapy for locally advanced triple negative breast cancer”	
2021	Lecturer, Cedars-Sinai Academic Programs, Academic HR Professional Development Workshop	
2021	Lecturer, SCCC Events, Komen Breast Cancer Forum, “Immune therapy strategies for the treatment of breast cancer”.	
2022	Lecturer, SCCC Solid Tumor Board Review Conference, “Emerging Role of Immunotherapy in Breast Cancer”.	
2022	Lecturer, Hamon Center for Therapeutic Oncology Research & Simmons Comprehensive Cancer Center Experimental Therapeutics Program, “Modern Immune Therapy Strategies for Breast Cancer”.	
2022	Introduction lecture, UT Southwestern Breast Surgery Oncology Fellowship Interviews	
<u>Formal Mentoring Activities</u>		
2014 – 2016	Mentor, Weill Cornell Medical College Women in Medicine Mentoring Program	
<u>Mentored in Research</u>		
2008-2012	Patrick Morris, MD	Dr. Morris was mentored during his Advanced Clinical Breast Cancer Research Fellowship at MSKCC in the authorship of numerous articles and the publication of several research projects (i.e. Morris PG, Lynch C, Feeney JN, et al. J Clin Oncol. 2010;28(19):3154-9 and McArthur HL, Mahoney KM, Morris PG, et al. Cancer.

		2011;117(24):5461-8). Dr. Morris is currently in academic clinical practice in Ireland.
2009-2011	Kathleen Mahoney, MD	Dr. Mahoney was mentored when she was an Internal Medicine Resident at Weill Cornell Medical College in a project entitled, “Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer” (McArthur HL, Mahoney KM, Morris PG, et al. Cancer 2011;117(24):5461-8). Dr. Mahoney subsequently completed her Medical Oncology Fellowship at the Dana Farber Cancer Institute in Boston, MA, and was thereafter hired to the faculty of that institution.
2010-2011	Melissa Accordino, MD	Dr. Accordino was mentored when she was an Internal Medicine Resident at Weill Cornell Medical College in a project entitled, “Hyperglycemia as a predictor of outcomes in patients with early stage breast cancer.” Dr. Accordino is currently an Attending Physician and Assistant Professor of Medicine at Columbia University Medical Center, New York, NY.
2010-2014	Adi Diab, MD	Dr. Diab was mentored during his Medical Oncology Fellowship and Advanced Clinical Breast Cancer Research Fellowship at MSKCC in the development and implementation of several research studies investigating immunotherapy in breast cancer. One of these studies, “A pilot study of pre-operative, single-dose ipilimumab and/or cryoablation in women with early stage/resectable breast cancer” was highlighted as a poster discussion at the 2014 Annual ASCO meeting. Dr. Diab was also awarded the 2012-2013 Terri Brodeur Breast Cancer Foundation Fellowship for this work. Dr. Diab is now a clinical investigator in immune therapy at MD Anderson Cancer Center in Houston, TX.
2013 - present	David Page, MD	Dr. Page was mentored in the development and implementation of several research studies investigating immunotherapy in breast cancer during his Medical Oncology Fellowship at MSKCC. In this capacity, Dr. Page has co-authored several published articles (i.e. Page DB, Naidoo J, McArthur HL. Immunotherapy 2014;6(2):195-209) and has been the recipient

		of numerous honors (the 2014-15 Terri Brodeur Breast Cancer Foundation Fellowship, 2014 ASCO Meeting Travel Award, 2014 ASCO Breast Merit Award, 2014 Adaptive Biotechnologies Young Investigator Award, and a 2014 AACR Scholar-in-Training Award). Dr. Page is now a Breast Cancer Immunotherapy Medical Oncologist at the Robert W. Franz Cancer Research Center. Mentorship and research collaboration continue.
2013 - present	Dana Dure, MD	Dr. Dure was mentored during her Internal Medicine residency at State University of New York Health Science Center at Brooklyn (SUNY Downstate) College of Medicine in a project entitled, "Monosomy 17 in breast carcinomas with HER2 amplification and its effects on response to Herceptin" which was presented at the 2014 San Antonio Breast Cancer Symposium and is pending publication.
2015-2016	Tracy Proverbs-Singh, MD	Dr. Proverbs-Singh was a MSKCC medical oncology fellow who was mentored in the conduct of an active clinical trial entitled, "A Phase 1b/2 study of intratumoral AdRTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer" and a correlative project entitled, "Evaluating the predictive and prognostic potential of novel immunologic tumor-based biomarkers in early stage breast cancer." She was awarded a 2016 ASCO Young Investigator Award for a project in immunotherapy and triple negative breast cancer. She is currently in private practice in New Jersey.
2015-2016	Emily Eichenberger, MD	Dr. Eichenberger was an Internal Medicine Resident at Weill Cornell Medical College who collaborated on a project investigating changes in tumor infiltrating lymphocytes (TILs) in response to neoadjuvant chemotherapy and a project exploring outcomes in women with HER2+ disease who receive radiation for breast cancer brain metastases.
2017-2019	Reva Basho, MD	Dr. Basho is junior faculty member at CSMC who has been mentored in a research program of immune therapy for HER2-positive brain metastases.

2017-2018	Jorge Leal, MD	Dr. Leal is a practicing breast medical oncologist from Brazil who was mentored in a one-year advanced clinical research fellowship in breast cancer at CSMC.
2018-2020	Erin Cobain, MD	Dr. Cobain is on faculty at the University of Michigan and is being mentored in the development of a study arm for a SWOG cooperative group investigator-initiated trial (RUSTIC).
2018-present	Kellie Spector, MD	Dr. Spector is an Internal Medicine resident at Cedars-Sinai and she is being mentored in the conduct of a retrospective study exploring the impact of mammogram frequency on early detection of a new primary in early stage breast cancer survivors.
2020-present	Alexis LeVee, MD	Dr. LeVee is an Internal Medicine resident at Cedars-Sinai and she is being mentored in the conduct of a retrospective study exploring the impact of neoadjuvant dual HER2-blockade with chemotherapy on HER2 status in the curative intent setting.
2021 – present	Sonya Reid, MD MPH	Dr. Reid is a Vanderbilt University junior faculty member in development and implementation of a clinical trial entitled, “Incorporating genomic signatures to guide management of HR+ MBC in a diverse cohort (INSIGHT).” Dr. Reid is being mentored with the support of the Bristol Myers Squibb Diversity in Clinical Trials Career Development Program (BMSF DCTCDP).
2022 – present	Prasanna G. Alluri, MD MPH	Dr. Alluri is an assistant professor in the Department of Radiation Oncology in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern seeking funding from Damon Runyon (Clinical Investigator Award) and ASTRO-BCRF (CDA) for her trail.
<u>Graduate Students</u>		
2016	Ivan Cohen	Mr. Cohen is a graduate student at the Gerstner Sloan Kettering graduate school who was mentored as part of the Sloan Kettering Institute GSK Clinical Mentorship program. With Dr. Ronald Blasberg I co-mentored Mr. Cohen in a research project entitled, “A translational project to explore the relationship between tumor glycolysis and immune

		modulation, a novel therapeutic strategy in breast cancer.”
2018-present	Jacob Comeaux	Jacob previously worked in data entry for the Cedars-Sinai breast research group. He obtained a MS in Human Genetics and Genetic Counseling (MSGC) at Keck Graduate Institute and is now a genetic counsellor at USC. Jacob is being mentored in the conduct of his IIT entitled, “CHEK: Comparing Rates of Risk Reducing Prophylactic Mastectomies (RRMs) among Women with Moderate-Penetrance Breast Cancer Susceptibility Gene Mutations based on Differing Family Histories of BrEaSt Cancer and Perceived RiSk.”
2021 – 2022	Tanner Reese	Thesis committee member for Tanner’s graduate project entitled, “Molecular drivers and novel therapeutic options for triple negative breast cancer brain metastases.”
<u>Medical Students</u>		
2008-2010	Colleen Lynch	Ms. Lynch was mentored when she was a Medical Student at the NYU School of Medicine in a project entitled, “Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer” [Morris PG, Lynch C, Feeney JN, et al. J Clin Oncol. 2010;28(19):3154-9]. Thereafter, Ms. Lynch went on to an Internal Medicine Residency at the University of California, San Francisco.
2010	Joanna Grabska	Ms. Grabska, a prior MSKCC employee and a visiting medical student from St. George’s University School of Medicine, was mentored in a project entitled, “Hyperglycemia as a predictor of outcomes in patients with early stage breast cancer.” Thereafter, Ms. Grabska went on to an Internal Medicine Residency at the University of Connecticut.

Invited Lectures

Year(s)	Title	Location
<u>International</u>		
09/24/2009	ECCO 15/ European Society for Medical Oncology (ESMO) 34 th Annual Meeting, “High resolution microarray copy number analysis (array CGH) suggests that determination of HER2	Berlin, Germany

	amplification FISH (FISH+) is inaccurate in human breast cancer specimens that are HER2 2+ by immunohistochemistry (IHC2+)." Berlin, Germany.	
11/09/2012	1 st Annual Wade Thompson Symposium for VTP Therapeutics in Oncology, "A clinical trial of cryotherapy with ipilimumab for localized breast cancer."	Rehovot, Israel.
11/04/2014	3 rd Annual Wade Thompson Symposium for VTP Therapeutics in Oncology, "Ablation and immunomodulation in breast cancer: Phase 1 trial results and design for further studies.	Oxford, England.
11/14/2014	Alberta Health Services/University of Calgary Oncology Visiting Speaker Series, "The emerging role of immune therapy in breast cancer."	Calgary, Canada
01/14/2016	University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, "The emerging role of immune therapy in breast cancer."	Toronto, Canada
10/10/2016	OBI Symposium at the 2016 ESMO Congress, "Rationale and development of the active immunotherapy Adagloxad Simolenin (OBI-822/821)."	Copenhagen, Denmark
09/15/2017	Canadian Immuno-Oncology Summit 2017. "Beyond Checkpoint Inhibitors – IO Combination with Chemotherapy, Radiation and Targeted Therapies" and "Immunotherapy in Breast Cancer."	Toronto, Canada
10/09/2017	Keynote 522 Investigators Meeting, "Scientific Background of Pembrolizumab (MK3475) in Triple Negative Breast Cancer and Rationale for Trial Design for KEYNOTE522."	Sao Paulo, Brazil
03/24/2018	GBECAM-LACOG Breast Cancer Conference : Official Best of San Antonio Breast Cancer Symposium, "Immunotherapy in breast cancer: rationale and perspectives."	Sao Paulo, Brazil
03/24/2018	GBECAM-LACOG Breast Cancer Conference : Official Best of San Antonio Breast Cancer Symposium, Keynote Lecture: "Breast Cancer Year in Review."	Sao Paulo, Brazil
07/14/2018	International Congress on the Future of Breast Cancer, "New insights into HER2-driven metastatic breast cancer."	San Diego, CA
10/19/2018	ESMO Annual Meeting Pan Tumor Satellite Symposium, "Emergent women's cancers therapies: Catalyst to transform standard of care."	Munich, Germany
08/27/2019	14 th Annual Breast Cancer Meeting, "Immunotherapy in triple negative breast cancer: clinical insights and sharing of experiences."	Sao Paulo, Rio de Janeiro and Gramado, Brazil
08/30/2019	14 th Annual Breast Cancer Meeting, "CDK4/6 inhibitors in the treatment of HER2-positive breast cancer."	Gramado, Brazil
02/01/2020	Canadian Breast Cancer Symposium, "Optimizing treatment of triple negative breast cancer."	Whistler, Canada

02/01/2020	Canadian Breast Cancer Symposium, “Update on immunotherapy in breast cancer.”	Whistler, Canada
10/29/2020	Breast Cancer Symposium – Pink October, “Modern Immune Therapy Strategies for the Treatment of Breast Cancer.	Virtual (Live-streamed in Brazil)
11/03/2020	OncInfo/Roche Brazil Webinar, “Immunotherapy in metastatic triple negative breast cancer: clinical insites and experience.”	Virtual (Brazil)
04/08/2021	Brazilian Breast Cancer Society: Brazilian Breast Conference. Moderator and invited speaker, “Why Neoadjuvant Treatment in Early Triple Negative Breast Cancer?”.	Virtual (Brazil)
04/14/2021	CAPItello-290 Investigator Meeting for the Americas	Virtual
07/16/2021	ESMO July Plenary Session, “Does the addition of pembrolizumab to neoadjuvant chemotherapy improve event-free triple-negative breast cancer?”	Virtual
10/06/2021	ESMO 2021 Rountable: Metastatic Triple-Negative Breast Cancer	Virtual
10/07/2021	Event MSD: Keytruda – Cancer de Mama Triple Negativo, “Pembrolizumab for early triple-negative breast cancer”.	Virtual (Argentina)
11/05/2021	JCAP Virtual CTIO TNBC webcast	Virtual (Japan)
11/30/2021	OncInfo/Breast Club Brazil Webinar – Clinical Case Discussion	Virtual (Brazil)
07/12/2022	Latin America CTIO: Advancing the Treatment of Early TNBC: the Immunotherapy Era scientific symposium, “What Has Changed in the Context of Immunotherapy in Early Stage on the Clinical Practice? – Case Discussion”.	Virtual (Brazil)
<u>National</u>		
09/08/2013	ASCO Breast Cancer Symposium, Meet the Professor, “Immunotherapy for breast cancer: Where are we and where are we heading?”	San Francisco, CA
05/30/2014	ASCO Annual Meeting Grant Writing Workshop, “What to do when your first grant application gets rejected.”	Chicago, IL
09/05/2014	ASCO Breast Cancer Symposium, “Immunologic checkpoint blockade strategies in breast cancer.”	Chicago, IL
05/29/2015	ASCO Annual Meeting Grant Writing Workshop, “What to do when your first grant application gets rejected.”	Chicago, IL
06/03/2016	ASCO Annual Meeting Grant Writing Workshop, “What to do when your first grant application gets rejected.” Chicago, IL.	Chicago, IL
04/21/2016	University of Washington, “The emerging role of immune therapy in breast cancer.”	Seattle, WA
02/23/2017	2017 ASCO-SITC Clinical Immuno-Oncology Symposium Oral Abstract Session Discussion.	Orlando, FL
06/02/2017	2017 ASCO Annual Meeting Grant Writing Workshop, “What to do when your first application gets rejected.”	Chicago, IL
06/16/2017	2017 Best of ASCO, “Breast cancer-local/regional/adjuvant.”	San Francisco, CA

09/26/2017	ASTRO Annual Meeting, “Biology of breast cancer: from bench to bedside.”	San Diego, CA
10/11/2017	SWOG Bi-Annual Meeting, “The Challenge of Immunotherapy in Breast cancer.”	Chicago, IL
11/02/2017	2nd JKTG-Wistar Institute Symposium on Research Driving New Diagnosis & Treatment of Metastatic Breast Cancer, “Current and future strategies with checkpoint blockade-mediated immune therapy in breast cancer.”	Bethesda, MD
11/02/2017	Alliance Immuno-Oncology working Group Meeting, “The Current State of Immuno-Oncology in Breast Cancer.”	Chicago, IL
11/11/2017	2017 Best of ASTRO Annual Meeting, “Breast cancer immunotherapy from a medical oncologist’s perspective.”	Miami, FL
03/23/2018	France Foundation Breast Cancer Summit. “Redefining breast cancer treatment with personalized medicine: triple negative breast cancer.”	Houston, TX
04/27/2018	France Foundation Breast Cancer Summit. “Redefining breast cancer treatment with personalized medicine: triple negative breast cancer.”	Philadelphia, PA
06/02/2018	ASCO Annual Meeting, “Novel cytokine-based combination strategies.”	Chicago, IL
06/04/2018	ASCO Annual Meeting, “Translating immunobiology into effective therapeutic strategies.”	Chicago, IL.
07/13/2018	Best of ASCO, “Breast cancer – metastatic.”	San Diego, CA
11/07/2018	AZ Immuno-Oncology Symposium, “Combining radiation with IO for breast cancer.”	Arlington, VA
11/08/2018	Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer Forward, “How is immunotherapy expected to change the treatment landscape for metastatic TNBC?”	New York, NY
12/06/2018	OncoLive Peer Exchange, “Expert perspectives on breast cancer.”	San Antonio, TX
01/26/2019	USC Breast Cancer Symposium, “Modern application of genomics for hormone receptor positive early stage breast cancer.”	Los Angeles, CA
05/04/2019	20 th Annual Meeting of the American Society of Breast Surgeons Satellite Symposium, "On the cusp of the era of immuno-oncology in triple-negative breast cancer: Rational strategies to make the most of immunotherapies and other effective treatment modalities throughout the disease continuum."	Dallas, TX
09/06/2019	2019 Best of Breast in the Pacific Northwest Symposium, “Modern immune therapy strategies for breast cancer.”	Seattle, WA
09/07/2019	DAVA Oncology Regional Summit Series on Breast Cancer, “Next-generation ADCs for TNBC”	Pasadena, CA

10/23/2019	Breast Cancer Treatment in 2019: New Advancements in Breast Cancer Management Symposium, “Innovations in breast cancer treatment.”	Los Angeles, CA
10/30/2019	ASCO 2019 Scientific and Career Development Retreat, “How to transition from early to mid-career.”	Alexandria, VA
11/01/2019	8th Annual New Therapeutics in Oncology Conference, “New therapies for breast cancer.”	Los Angeles, CA
05/31/2020	2020 ASCO Annual Conference, “ASCO Highlights of the Day: Developmental Therapeutics - Immunotherapy”.	Virtual
07/27/2020	21st Annual Meeting of The American Society of Breast Surgeons, “Navigating the New Era of Immuno-Oncology in TNBC: Clinical Updates on Immunotherapy as a Component of Multimodal Therapy in Advanced and Early-Stage Disease and Practical Guidance for Breast Surgeons.	Virtual
07/29/2020	2020 Society of Surgical Oncology (SSO) Annual Cancer Symposium, “The Era of Immuno-Oncology TNBC Has Begun: Essential Guidance For Surgeons on How to Maximize the Potential of Immunotherapies and Combinations in Advanced and Early-Stage Disease.”	Virtual
07/31/2020	19th Annual International Congress on the Future of Breast Cancer® WEST, “Optimizing Immunotherapy for Metastatic Breast Cancer.” Virtual due to COVID19.	Virtual
08/01/2020	19th Annual International Congress on the Future of Breast Cancer® WEST, “The Nexus of Immunotherapy and Radiation Therapy for Oligometastatic Disease.”	Virtual
08/28/2020	Japan/China/Asia-Pacific Merck Scientific Symposium TNBC Webcast, “Neoadjuvant Therapy in TNBC.”	Virtual
09/24/2020	2020 ESMO Annual Conference, ESMO Breast Cancers Roundtable Discussion.	Virtual
04/23/2021	Great Debates and Updates in Women’s Oncology, hosted by AstraZenica, moderator: “Triple Negative Breast Cancer”, debater: “Immunotherapy for Early Triple Negative Breast Cancer – Is it Ready for Prime Time.”	Virtual
05/06/2021	The Society for Immunotherapy of Cancer (SITC): Advances in Cancer Immunotherapy (ACI Regional Series, Los Angeles, “Immunotherapy for the Treatment of Additional Solid Tumors.”	Virtual
05/10/2021	US Medical Affairs Breast Preceptorship on Behalf of OncLive, “Current Treatment Recommendations – Place in Treatment and Considerations for Newer Therapies.”	Virtual
06/05/2021	Global Daily Highlights: Oncology Education pan-tumour discussion of ASCO Highlights Panellist	Virtual
06/22/2021	Panelist, ASCO Breast Roundtable, presented by Oncology Education.	Virtual

06/22/2021	Institutional Perspectives in Cancer presented by OncLive, “Triple negative breast cancer”.	Virtual
09/30/2021	Lynn Sage Breast Cancer Symposium, “Incorporating immunotherapy into practice”.	Virtual
10/04/2021	Breast Cancer Summit: New Wave of Breast Cancer Targets. “Looking for new targets in TNBC”.	Virtual
10/08/2021	Women’s Oncology GDU: Immunotherapy for early triple negative breast cancer – is it ready for prime time?	Virtual
12/01/2021	SITC 2021, Expert Panel Member: Case studies in immunotherapy for the treatment of breast cancer – CPG Webinar	Virtual
12/08/2021	SABCS Expert Panel Member: VJ Oncology Roundtable	Virtual
12/08/2021	SABCS Expert Panel Member: Health Equity Roundtable	Virtual
12/09/2021	SABCS Educational Section, “Clinical Updates on Immunotherapy”	Virtual
12/16/2021	Moderator, MJH Events: Targeted Oncology Breast Cancer Case-Based Roundtable	Virtual
12/16/2021	Expert panelist, OncLive SABCS “Talk” Panel on HER2+ Breast Cancer	Virtual
01/19/2022	Expert panelist, OncologyEducation x SABCS 2021 Roundtable	Virtual
01/20/2022	Expert panelist, Targeted Oncology Virtual Tumor Board on Early Breast Cancer	Virtual
01/29/2022	Keynote address, Ohio State’s Update from the 2021 San Antonio Breast Cancer Symposium, “Emerging Role of Immunotherapy in Breast Cancer”.	Virtual
03/04/2022	PER Medical Crossfire: Selecting and Sequencing Therapies Across the Disease Continuum of HER2+ Breast Cancer, “Managing the Patient with Early-Stage HER2+ Breast Cancer Who Goes Directly to Surgery”.	Miami, FL
03/05/2022	PER MBC Satellite Symposium: Integrating New Treatment Options into the Management of Triple Negative Breast Cancer: An Expert Tumor Board Discussion. “Case 1: Patient with High-Risk Early-stage TNBC and panel discussion”	Miami, FL
03/09/2022	Expert panelist, MedscapeTV SABCS Recap of Breast Cancer	Virtual
03/24/2022	MDCSCO and Maryland Breast Cancer Consortium Breast Cancer Update 2022 Featured Speaker.	Hanover, MD
04/08/2022	PeerView CME PARP Inhibitors Breast Cancer Symposium, “Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management of Breast Cancer” panalist.	Las Vegas, NV
06/05/2022	Program Chair, CCO Symposium at ASCO, “From Biomarkers to Treatment: The New Need-to-Know in Early Breast Cancer.	Chicago, IL

06/25/2022	2022 ASCO Direct Annual Meeting Review, “Breast Cancer – Adjuvant”.	San Antonio, TX
07/08/2022	Panelist, Chicago 2022 Breast Cancer Roundtable Discussion, presented by OncologyEducation.	Virtual
07/14/2022	Panelist, OncLive Scientific Roundtable Workshop, “Practical Approaches to Treating Patients with Breast Cancer”.	New York, NY
07/16/2022	21 st Annual International Congress on the Future of Breast Cancer EAST, “Innovations to Improve Efficacy of Immune Checkpoint Inhibitors in Breast Cancer”.	New York, NY
07/30/2022	21 st Annual International Congress on the Future of Breast Cancer WEST, “Innovations to Improve Efficacy of Immune Checkpoint Inhibitors in Breast Cancer”.	San Diego, CA
<u>Regional/Local</u>		
02/27/2008	Columbia University Medical Center, “Current clinical challenges in cardiotoxicity evaluation and HER2 status determination in breast cancer.”	New York, NY
08/05/2008	Harvard School of Public Health, “Selected targeted therapies in breast cancer.”	Boston, MA
09/14/2010	Oncology Today: Current Issues in Clinical Oncology: Expert Review from Chicago 2010, “Updates in breast cancer.”	Albany, NY
01/06/2011	Living Beyond Breast Cancer, “News from the San Antonio Breast Cancer Symposium.”	New York, NY
11/06/2014	Chemotherapy Foundation Symposium, “Checkpoint inhibition in breast cancer.”	New York, NY
03/30/2016	2016 SASS Foundation Scientific Program, “The emerging role of modern immune therapy strategies in breast cancer.”	New York, NY
05/24/2016	Breast and colorectal oncology workshop, hosted by the Bobst International Center at MSKCC, “Immunotherapy.”	New York, NY
06/24/2016	Cedars-Sinai Medical Grand Rounds, “The emerging role of immune therapy in breast cancer.”	Los Angeles, CA
02/26/2017	69 th Los Angeles Radiological Society Midwinter Conference and CRS Leadership Summit “The emerging role of immune therapy in breast cancer.”	Pasadena, CA
05/09/2017	19 th Annual Board of Governors Healthcare College, “The emerging role of immune therapy in the treatment of breast cancer.”	Los Angeles, CA
06/22/2017	Cancer Care, “Current perspectives on early stage breast cancer.”	Los Angeles, CA
06/23/2017	Benjamin Center Breast Panel, “Recent advances in treatment/management.”	Los Angeles, CA
11/04/2017	6 th Annual New Therapeutics in Oncology: The Road to Personalized Medicine Conference, “Integration of immune therapies in the treatment of breast cancer.”	Los Angeles, CA

11/13/2017	Breast Cancer Treatment in 2017: How to Minimize Side Effects and Maximize Quality of Life, “Harnessing the immune system against breast cancer.”	Los Angeles, CA
02/09/2018	France Foundation Breast Cancer Summit. “Redefining breast cancer treatment with personalized medicine: triple negative breast cancer.”	Los Angeles, CA
02/16/2018	UF College of Medicine 23 rd Annual Multidisciplinary Symposium on Breast Disease, “Breast cancer immunotherapy: A multidisciplinary approach.”	Amelia Island, FL
02/20/2018	38 th Scripps Annual Clinical Hematology and Oncology Conference, “Management of heterogeneous breast cancers.”	San Diego, CA
05/09/2018	IMpassion030/WO39391 Investigator Meeting, “Tumor immunotherapy and rationale for use in TNBC.”	Chicago, IL
06/28/2018	CME Live Summit Series, “Leveraging relevant biological factors in the treatment of early HER2-positive breast cancer: closing the quality chasm.”	Los Angeles, CA
07/14/2018	Roundtable discussion, “Update on TailoRx.”	San Diego, CA
07/20/2018	Providence Cancer Center, “Immunotherapy strategies in breast cancer.”	Portland, OR
09/27/2018	Breast Cancer Treatment in 2018: New Frontiers in Breast Cancer Management, “Harnessing the immune system against breast cancer.”	Los Angeles, CA
01/30/2019	Vumedi, “Modern immune therapy strategies for breast cancer.”	Los Angeles, CA
05/09/2019	Med Learning Group CME program, “An animated whiteboard view of cancer immunotherapy: treating triple negative breast cancer.”	Philadelphia, PA
05/10/2019	2019 Alliance Fall Group Meeting, IO Committee, “IO update in breast cancer.”	Chicago, IL
09/09/2019	OncoLive Regional Seminar Series, “Refining the use of CDK4/6 inhibitors in metastatic breast cancer.”	Santa Monica, CA
09/30/2019	Chair, Oncology Education ESMO 2019 - Breast Roundtable Discussion	Virtual
12/16/2019	PracticeUpdate Commentary Interview, “Updates in neoadjuvant management of triple-negative Breast Cancer”.	Virtual
12/23/2019	Practice Update Commentary Interview, “Optimizing immunotherapy for the treatment of metastatic triple-negative breast cancer.”	Virtual
01/28/2020	2020 SU2C Scientific Summit, “Combining Radiotherapy and Immune Therapy with CDK4/6 Blockade in Breast Cancer.”	Los Angeles, CA
02/18/2020	Scripps MD Anderson Cancer Center’s Clinical Hematology & Oncology Conference, “Optimizing treatment of triple negative breast Cancer.”	La Jolla, CA.

03/01/2020	2020 International Society of Breast Pathology USCAP Companion meeting. “New trends in HER2-targeted therapy for HER2+ breast cancer.”	Los Angeles, CA
03/02/2020	USCAP Annual Meeting Satellite Symposium, “Evolving landscape of HER2-targeted therapies and the emergence of HER3 and TROP2 as new therapeutic targets in breast cancer: state of the science.”	Los Angeles, CA
10/14/2020	Regional California Black Chamber of Commerce SFV, Roundtable: “State of Healthcare” Panel.	Virtual
11/05/2020	38th Annual CFS: Innovative Cancer Therapy for Tomorrow Symposium, “Immunotherapy: Where are we and where are we going.”	Virtual
11/11/2020	OncInfo Virtual Preceptorship Program on Breast Cancer Management in 2020, “Curative Intent Systemic Therapy Updates.”	Virtual
11/12/2020	OncInfo Virtual Preceptorship Program on Breast Cancer Management in 2020, “mTNBC Systemic Therapy Update.”	Virtual
12/04/2020	Stanford University Special Oncology Seminar, “Modern Immune Therapy Strategies for the Treatment of Breast Cancer.”	Virtual
12/08/2020	Clinical Care Options CME program, “New Data, New Opportunities, and New Clinical Challenges Using Immunotherapies for Triple-Negative Breast Cancer.”	Virtual
02/06/2021	University of Kansas Cancer Center Post San Antonio Review, “Treatment Updates for HER2 Positive Breast Cancer: Changing Paradigms.”	Virtual
02/19/2021	Cedars-Sinai Pathology and Laboratory Medicine Grand Rounds, “Immune Therapy Strategies for Breast Cancer.”	Los Angeles, CA
02/21/2021	Scripps: Clinical Hematology & Oncology: 2021, “Optimizing Immunotherapy for Metastatic Breast Cancer.”	Virtual
04/06/2021	Panelist, UCLA Jonsson Comprehensive Cancer Center, “Women in Oncology Panel”.	Virtual
03/10/2022	UT Southwestern Society for Surgical Oncology (SSO), “KEYNOTE-522: Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer and Q&A”.	Dallas, TX
03/11/2022	UT Southwestern Society for Surgical Oncology (SSO), “Translating Progress with Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer”.	Dallas, TX
03/22/2022	2022 Carolyn P. Horchow Women’s Health Symposium, “Putting the Body’s Defenses to Work: Mobilizing the Immune System to Treat Breast Cancer”.	Dallas, TX

04/09/2022	Opinions in Breast Cancer: An Interactive Regional Forum presented by Curio, “Polling and Group Discussion: Management of Patients with HER2 Breast Cancer”.	Dallas, TX
04/12/2022	Chair and Featured Speaker, OncLive State of the Science Summit: Breast Cancer, “Early Stage HER2+ Breast Cancer”.	Dallas, TX
05/10/2022	Co-Moderator, Curio Opinions in mTNBC: An Interactive Local Workshop	Dallas, TX

Bibliography

Peer-Reviewed Publications

Original Research Articles

1.	McArthur HL and Kennecke HF. Rationale for extended adjuvant letrozole after five years of tamoxifen in postmenopausal, oestrogen receptor-positive women with early stage breast cancer. <i>Current Oncology</i> 2005;12(3):1-4.
2.	McArthur HL , Chou SH, Southern DA, Ghali WA and Lemaire J. Who looks after me? The impact of a communication tool on a medical teaching unit. <i>J Healthc Qual.</i> 2006; W1-6.
3.	Hudis C, McArthur H , Dang C. Current status of the taxanes as adjuvant therapy for breast cancer. <i>Breast</i> 2007;16:S132-135.
4.	McArthur HL and Chia S. Cardiotoxicity of trastuzumab in clinical practice. <i>N Engl J Med</i> 2007;357(1):94-5.
5.	McArthur HL and Hudis CA. Adjuvant chemotherapy for early-stage breast cancer, in Seidman AD (ed): <i>Hematol Oncol Clin North Am.</i> New York, NY, Elsevier Inc 2007;21(2):207-22.
6.	McArthur HL and Hudis CA. Has first-line therapy had an impact on general outcome in metastatic breast cancer? <i>Future Oncol</i> 2007;3(4):411-8.
7.	McArthur HL and Hudis CA. Dose-dense therapy in the treatment of early-stage breast cancer: An overview of the data. <i>Clin Breast Cancer.</i> 2007;8 (Suppl 1):S6-S10.
8.	McArthur HL and Hudis CA. Updates in adjuvant systemic treatment of breast cancer. <i>Update on Cancer Therapeutics.</i> 2007;2(4):193-199.
9.	McArthur HL and Hudis CA. Breast cancer chemotherapy. <i>Cancer J.</i> 2007;13(3):141-7.
10.	McArthur HL and Hudis CA. Advances in adjuvant chemotherapy of early stage breast cancer. <i>Cancer Treat Res.</i> 2008;141:37-53.
11.	Kennecke H, McArthur HL , Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA. Risk of early recurrence among postmenopausal women with estrogen receptor positive early breast cancer treated with adjuvant tamoxifen. <i>Cancer.</i> 2008;112(7):1437-44.
12.	McArthur HL and Dickler MN. Biomarkers in breast cancer. <i>Cancer Biol Ther.</i> 2008;7(1):21-2.
13.	McArthur HL and Dickler MN. The evolving role of lapatinib in the management of women with HER2-positive breast cancer. <i>AJHO.</i> 2008;7(12):561-4.
14.	McArthur HL , Gelmon KA, Olivotto IA, Speers CH, Ellard SL, O'Reilly SE, Kennecke HF. Effectiveness of a letter notification program for women with early stage breast cancer eligible for extended adjuvant letrozole. <i>J Clin Oncol.</i> 2009;27(9):1388-93.

15.	Morris PG, Dickler M, McArthur HL , Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. <i>J Clin Oncol</i> . 2009;27(36):6117-23.
16.	McArthur HL , Hudis CA. Trastuzumab: A picky partner? <i>Clin Cancer Res</i> . 2009;15(20):6311-3.
17.	Morris PG, McArthur HL , Hudis CA. Therapeutic options for metastatic breast cancer. <i>Expert Opin Pharmacother</i> . 2009;10(6):967-81.
18.	McArthur HL . An overview of HER-targeted therapy with lapatinib in breast cancer. <i>Adv Ther</i> . 2009;26(3):263-271.
19.	Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM, Dickler M, Hudis CA, Jochelson M, McArthur HL . Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. <i>J Clin Oncol</i> . 2010;28(19):3154-9.
20.	McArthur HL . Update on administration of adjuvant trastuzumab. <i>Clin Adv Hematol Oncol</i> . 2010;8(5):321-2,375.
21.	Morris PG, McArthur HL , Hudis C, Norton L. Dose-dense chemotherapy for breast cancer: What does the future hold? <i>Future Oncol</i> . 2010;6(6):951-65.
22.	McArthur HL , Morris PG. Aromatase inhibitor strategies in metastatic breast cancer. <i>Int J Women's Health</i> . 2010;1:67-72.
23.	McArthur HL , Hudis CA. Chemotherapy: Neoadjuvant trial design: Time for a brave new world? <i>Nat Rev Clin Oncol</i> . 2010;7(7):359-60.
24.	McArthur HL , Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. <i>Clin Cancer Res</i> . 2011;17(10):3398-407.
25.	McArthur HL , Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis, CA. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. <i>Cancer</i> . 2011;117(24):5461-8.
26.	Morris PG, Chen C, Steingart R, Fleisher M, Lin M, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL , Winer E, Norton L, Hudis CA, Dang CT. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. <i>Clin Cancer Res</i> 2011;17(10):3490-3499.
27.	Morris PG, McArthur HL . Trastuzumab and chemotherapy may be appropriate for small, node-negative, HER2-positive breast cancer. <i>Oncologist</i> 2012;17(10):e33.
28.	Kiess AP, McArthur HL , Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. <i>Cancer</i> 2012;15;118(8):1982-8.
29.	Morris PG, Ulaner GA, Eaton A, Fazio M, Jhaveri K, Patil S, Evangelista L, Park JY, Serna-Tamayo C, Howard J, Larson S, Hudis CA, McArthur HL , Jochelson MS. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <i>Cancer</i> 2012;118(22):5454-5462.

30.	Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis CA, McArthur HL , Chang J, Rimawi M, Vornik L, Comelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SC, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with hormone receptor–negative breast cancer. <i>Cancer Prev Res</i> 2012;5(9):1144-1154.
31.	Diab A, Solomon S, Allison J, Norton L, and McArthur HL . Interventional immunotherapy in breast cancer. <i>Breast Cancer Manage.</i> 2012;1(4):257-260.
32.	Page DB, Naidoo J, McArthur HL . Emerging immunotherapy strategies in breast cancer. <i>Immunotherapy</i> 2014;6(2):195-209.
33.	Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL , Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signaling in women with hormone receptor-negative breast cancer. <i>J Hum Nutr Diet.</i> 2015;28(3):272-82.
34.	McArthur HL , Morris PG, Hudis CA. Combination trastuzumab and chemotherapy may have a role in women with small, node negative, HER2 positive breast cancer. <i>J Clin Oncol.</i> 2015;33(1):124-5.
35.	Lanning RM, Morrow M, Riaz N, McArthur HL , Dang C, Moo TA, El-Tamer M, Krause K, Siu C, Hsu M, Zhang Z, Pei X, McCormick B, Powell SN, Ho A. The effect of adjuvant trastuzumab on locoregional recurrence of human epidermal growth factor receptor 2-positive breast cancer treated with mastectomy. <i>Ann Surg Oncol.</i> 2015;22(8):2517-25.
36.	Sanchez K, Page D, McArthur HL . Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. <i>Curr Probl Cancer</i> 2016; 40(2-4):151-162.
37.	Linker K, Riedl C, Ong L, Jochelson M, Ulaner GA, McArthur HL , Dickler M, Gönen M, Weber WA. Impact of the number of lesions analyzed in metastatic breast cancer on response assessment by 18FFDG PET/CT using PERCIST. <i>J Nucl Med.</i> 2016;57(7):1102-4.
38.	Ulaner GA, Hyman D, Ross D, Corben A, Chandarlapaty S, Goldfarb S, McArthur HL , Erinjeri J, Solomon S, Kolb H, Lyashchenko S, Lewis J, Carrasquillo J. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using the 89Zr-DFO-trastuzumab PET/CT. <i>J Nucl Med.</i> 2016;57(10):1523-1528.
39.	Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL , Jochelson M, Weber WA. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. <i>Am J Nucl Med Mol Imaging.</i> 2016;6(2):120-7.
40.	McArthur HL . Checkpoint inhibitors in breast cancer: Hype or promise? <i>Clin Adv Hematol Oncol.</i> 2016;14(6):392-5.
41.	Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris E, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, McArthur HL . Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. <i>Cancer Immunol Res.</i> 2016;4(10):835-844.
42.	Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL . Adjuvant chemotherapy and trastuzumab is safe and effective in older women with small, node-negative, HER2-positive early-stage breast cancer. <i>Clin Breast Cancer.</i> 2016;S1526-8209(16)30206-3.
43.	McArthur HL , Diab A, Page DB, Yuan J, Solomon S, Wong P, Comstock C, Durack J, Sung J, Maybody M, Morris E, Brogi E, Sacchini V, Morrow M, Patil S, Wolchok J, Allison J, Sharma P, Hudis C, Norton L. A pilot study of preoperative single-dose ipilimumab and/or

	cryoablation in women with early-stage breast cancer: A comprehensive immune profiling translational science approach to providing proof-in-concept. <i>Clin Cancer Res.</i> 2016;22(23):5729-5737.
44.	McArthur HL. Breast cancer brain metastasis: An ongoing clinical challenge and opportunity for innovation. <i>Oncology.</i> 2016;30(10).
45.	McArthur HL, Page D. Immunotherapy for the treatment of breast cancer: Checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. <i>Clin Adv Hematol Oncol.</i> 2016;14(11):922-933.
46.	Hu ZI, McArthur HL, Ho AY. The abscopal effect of radiation therapy: What is it and how can we use it in breast cancer? <i>Current Breast Cancer Reports.</i> 2017;9(1):45-51.
47.	Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, McArthur HL, Goene M. Comparison of FSG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. <i>Eur J Nucl Med Mol Imaging.</i> 2017;44(9):1428-1437.
48.	Hu ZI, Ho AY, McArthur HL. Combined radiotherapy and immune checkpoint blockade therapy for breast cancer. <i>Int J Radiat Oncol Biol Phys.</i> 2017;99(1):153-164.
49.	Morikawa A, Wang R, Patil S, Diab A, Yang J, Hudis C, McArthur HL, Beal K, Seidman AD. Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer and brain metastases in the era of HER2 targeted therapy: An argument for earlier detection. <i>Clin Breast Cancer.</i> 2018;18(5):353-361.
50.	Page DB, Wen H, Brogi E, Dure D, Ross D, Spinelli KJ, Patil S, Norton L, Hudis C, McArthur HL. Monosomy 17 in potentially curable HER2-amplified breast cancer: Prognostic and predictive impact. <i>Breast Ca Res Treat.</i> 2018;167(2):547-554.
51.	McArthur HL. Innovations and challenges in the treatment of metastatic triple-negative breast cancer. <i>J Oncol Pract.</i> 2018;14(5):290-291.
52.	Hu ZI, McArthur HL. Immunotherapy in breast cancer: the new frontier. <i>Curr Breast Cancer Rep.</i> 2018;10(2):35-40.
53.	Basho RK, McArthur HL. Optimizing (neo) adjuvant treatment of HER2-positive breast cancer. <i>Ther Adv Med Oncol.</i> 2018;10:1758835918775697.
54.	Recht A, McArthur H, Solin LJ, Tendulkar R, Whitley A, Giuliano A. Contemporary guidelines in whole-breast irradiation: an alternative perspective. <i>Int J Radiat Oncol Biol Phys.</i> 2019;104(3):567-573.
55.	Force J, Leal JHS, McArthur HL. Checkpoint blockade strategies in the treatment of breast cancer: where we are and where we are heading? <i>Curr Treat Options in Oncol.</i> 2019;20(4):35.
56.	Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA. Current landscape of immunotherapy in breast cancer: A review. <i>JAMA Oncol.</i> 2019;5(8):1205-1214.
57.	Higenell V, Fajzel R, Batist G, Cheema P, McArthur HL, Melosky B, Morris D, Petrella T, Sangha RS, Savard MF, Sridhar SS, Stagg J, Stewart DJ, Verma S. A network approach to developing immuno-oncology combinations in Canada. <i>Curr Oncol.</i> 2019;26(2):73-79.
58.	Page, D, Bear H, Prabhakaran S, Gatti-Mays, M, Thomas A, Cobain E, McArthur H, Balko J, Gameiro S, Nanda R, Gulley J, Kalinsky K, White J, Litton J, Chmura S, Polley M, Vincent B, Cescon D, Disis M, Sparano J, Mittendorf E, Adams S. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>NPJ Breast Cancer.</i> 2019;5:34.
59.	Gatti-Mays M, Balko J, Gameiro S, Bear H, Prabhakaran S, Fukui J, Disis M, Nanda R, Gulley J, Kalinsky K, Abdul Sater H, Sparano J, Cescon D, Page D, McArthur H, Adams S,

	Mittendorf E. If we build it they will come: targeting the immune response to breast cancer. <i>NPJ Breast Cancer</i> . 2019;5:37.
60.	Ho AY, Barker C, Arnold B, Powell S, Hu Z, Gucalp A, Lebron-Zapata L, Wen H, Kallman C, D'Agnolo A, Zhang Z, Flynn J, Dunn S, McArthur HL . A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in metastatic triple negative breast cancer. <i>Cancer</i> . 2020;126(4):850-860.
61.	Schmid P, Cortes J, Pusztai L, McArthur H , Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. <i>N Engl J Med</i> . 2020; 382(9):810-821.
62.	Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H , Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M; International Immuno-Oncology Biomarker Working Group. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>J Pathol</i> . 2020;250(5):667-684.
63.	Autio KA, Klebanoff CA, Schaer D, Kauh J, Slovin SF, Adamow M, Blinder VS, Brahmachary M, Carlsen M, Comen E, Danila DC, Doman TN, Durack JC, Fox JJ, Gluskin JS, Hoffman DM, Kang S, Kang P, Landa J, McAndrew PF, Modi S, Morris MJ, Novosiadly R, Rathkopf DE, Sanford R, Chapman SC, Tate CM, Yu D, Wong P, McArthur HL . Immunomodulatory activity of a colony-stimulating factor-1 receptor Inhibitor in patients with advanced refractory breast or prostate cancer: A phase 1 study. <i>Clin Cancer Res</i> . 2020; 26(21):5609-5620.
64.	Isaacs J, Anders C, McArthur H , Force J. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. <i>Curr Treat Options Oncol</i> . 2021;22(5):38.
65.	Nguyen AT, Shiao SL, McArthur HL . Advances in Combining Radiation and Immunotherapy in Breast Cancer. <i>Clin Breast Cancer</i> . 2021;21(2): 143-152.
66.	Chun B, Pucilowska J, Kim I, Chang S-C, Koguschi Y, Redmond WL, Bernard B, Rajamanickam V, Polaske N, Fields PA, Conrad V, Schmidt M, Urba W, Conlin A, McArthur H , Page D. Peripheral T cell diversity in early stage and metastatic breast cancer. <i>Cancer Res</i> 2021;81(4 Suppl) PS17-07.
67.	Kim I, Rajamanickam V, Bernard B, Chun B, Wu Y, Martel M, Sun Z, Redmond W, Sanchez K, McArthur H , Page DB. A case series of metastatic metaplastic breast carcinoma treated with anti-PD-1 therapy. <i>Front Oncol</i> . 2021;8;11:635237.
68.	Leal JHS; Gifone M; Leitão G; Fuzita W; McArthur, HL . Systemic Treatment of Hormone Receptor-Positive HER2-Negative Breast Cancer Brain Metastases in the Targeted Therapy Era. <i>Clin Breast Cancer</i> . 2021.
69.	Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL , Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ Jr, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA. Chemotherapy and targeted therapy for patients with human

	epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update. <i>J Clin Oncol</i> . 2021; 10;39(35):3938-3958.
70.	Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL , Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. <i>J Immunother Cancer</i> . 2021; 9(8):e002597.
71.	Chun B, Pucilowska J, Chang S, Kim I, Benjamin N, Koguchi Y, Redmond WL, Bernard B, Rajamanickam V, Polaske N, Fields PA, Conrad V, Schmidt M, Urba WJ, Conlin AK, McArthur HL , Page DB. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer. <i>J Immunother Cancer</i> . 2022; 10(1):e004033.
72.	Simmons C, Rayson D, Joy AA, Henning JW, Lemieux J, McArthur H , Card PB, Dent R, Brezden-Masley C. Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. <i>Ther Adv Med Oncol</i> . 2022; 14:17588359211066677.
73.	Schmid P, Cortes J, Dent R, Puzsai L, McArthur H , Kummel S, Bergh J, Denkert C, Park YH, Rui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J. Event-free survival with Pembrolizumab in early triple-negative breast cancer. <i>N Engl J Med</i> 2022;386:556-67.
74.	Page DB, Beal K, Linch SN, Spinelli KJ, Rodine M, Halpenny D, Modi S, Patil S, Young RJ, Kaley T, Merghoub T, Redmond D, Wong P, Barker CA, Diab A, Norton L, McArthur HL . Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases. <i>NPJ Breast Cancer</i> . 2022;8(1):50.
75.	Comeaux J, Culver J, Lee J, Dondanville D, McArthur HL , Quinn E, Gorman N, Ricker C, Li M, Lerman C. Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes. <i>Molecular Genetics & Genomic Medicine</i> . 2022; e2031.

Abstracts

1.	McArthur HL , Chou S, Poon MC, Southern DA and Mackay EA. Assessment of indications cited for thrombophilia screening in an urban health region. <i>Blood</i> 2003;102(11). Abstract 4137.
2.	McArthur HL , Chhanabhai M, Gascoyne RD, Connors JM and Savage KJ. Evaluation of a new prognostic index for peripheral T-cell lymphoma, unspecified (PTCL-US). <i>Blood</i> 2005;106(11). Abstract 2812.
3.	McArthur HL , Barnett J and Chia S. A population-based study of adjuvant trastuzumab-mediated cardiotoxicity among early stage HER2+ breast cancer patients. 2005 AACR San Antonio Breast Cancer Symposium. Abstract 2098.
4.	McArthur HL , Olivotto IA, Gelmon KA, Speers CH, Chia S, Ellard S and Kennecke HF. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. 2006 AACR San Antonio Breast Cancer Symposium. Abstract 3001.

5.	McArthur HL , Barnett J and Chia S. A population-based study of adjuvant trastuzumab-mediated cardiotoxicity among early stage HER2+ breast cancer patients. 2006 ASCO Annual Meeting. Abstract 10640.
6.	McArthur HL , Speers CH, Gelmon KA, Barnett J, Ellard SL, Olivotto IA, O'Reilly S and Kennecke HF. The a with early stage breast cancer eligible for extended adjuvant letrozole. 2006 AACR San Antonio Breast Cancer Symposium. Abstract 4043.
7.	McArthur HL , Hensley M, Brown CL, Chi DS, Offit K, Hurley K, Li Y, Gemignani ML, Robson ME and Barakat RR. Impact of risk-reducing oophorectomy on quality-of-life in women at risk for ovarian cancer. J Clin Oncol 2007;25(18S). Abstract 1520.
8.	McArthur HL , Rugo H, Paulson M, Rourke M, Traina T, Panageas K, Zhou Q, Steingart R, Dang C, Fornier M, Park J, Moasser M, Melisko M, Sugarman S, Norton L, Hudis C, and Dickler M. Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with breast cancer. 2007 AACR San Antonio Breast Cancer Symposium. Abstract 3065.
9.	Sierecki MR, Rugo HS, McArthur HL , Traina TA, Paulson M, Rourke M, Norton L, Seidman AD, Hudis CA, and Dickler MN. Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC). 2008 ASCO Annual Meeting. Abstract 589.
10.	Morris PG, Dickler MN, McArthur HL , Traina TA, Nulsen B, Steingart RM, Rugo HS, Norton L, Hudis CA, and Dang CT. <u>Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC).</u> 2008 ASCO Annual Meeting. Abstract 637.
11.	McArthur HL , Estilo C, Huryn J, Williams T, Fornier M, Traina TA, Howard J, Hudis CA, and Dickler MN. <u>Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate-and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC).</u> 2008 ASCO Annual Meeting. Abstract 9588.
12.	Morris PG, Dickler M, McArthur HL , Traina T, Godfrey L, Steingart R, Rugo H, Lin N, Moy B, Come S, Sugarman S, Norton L, Hudis CA, Dang C. <u>Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: No evidence of short-term changes in left ventricular ejection fraction.</u> 2008 AACR San Antonio Breast Cancer Symposium. Abstract 4102.
13.	McArthur HL , Tan LK, Patil S, Wigler M, Hudis CA, Hicks J, Norton L. High resolution Representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 co-amplification is uncommon in human breast cancer. 2008 AACR San Antonio Breast Cancer Symposium. Abstract 2023.
14.	McArthur HL , Morris PG, Patil S, Howard J, Mahoney K, Conlin AK, Norton L, Hudis CA. Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer. 2009 ASCO Breast Cancer Symposium. Abstract 228.
15.	Dickler MN, McArthur HL , Nulsen B, Patil S, Sealey J, Laragh J, Merali C, Steingart R, Hudis C, Rugo H. Evaluation of the correlation of baseline blood pressure (BP) and plasma renin activity (PRA) with bevacizumab (B)-mediated hypertension in patients with early-stage breast cancer. 2009 ASCO Annual Meeting. Abstract 602.
16.	McArthur HL , Brogi E, Patil S, Wigler M, Norton L, Hicks J, Hudis CA. High resolution microarray copy number analysis (array CGH) suggests that determination of HER2 amplification by FISH (FISH+) is inaccurate in human breast cancer specimens that are

	HER2 2+ by immunohistochemistry (IHC2+). <u>ECCO 15 and 34th ESMO Multidisciplinary Congress</u> ; Berlin, Germany. September 20-24, 2009. Abstract 1005.
17.	McArthur HL , Morris PG, Patil S, Howard J, Mahoney K, Conlin AK, Norton L, Hudis CA. Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer. 2009 Breast Cancer Symposium: San Francisco, CA; October 9-10, 2009. Abstract 228.
18.	McArthur HL , Rugo H, Nulsen B, Patil S, Steingart R, Melisko M, Grothusen J, Traina T, Norton L, Hudis CA, Dickler MN. Troponins do not predict cardiotoxicity in a pilot study of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P). 2009 AACR San Antonio Breast Cancer Symposium. Abstract 3087.
19.	McArthur HL , Brogi E, Patil S, Wigler M, Norton L, Hicks J, Hudis CA. High resolution comparative genomic hybridization (CGH) indicates that genomic profiles are very heterogeneous for HER2 and TOP2A in FISH-amplified human breast cancer specimens. 2009 AACR San Antonio Breast Cancer Symposium. Abstract 3165.
20.	McArthur HL , Rugo H, Nulsen B, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Park J, Moasser M, Melisko M, Sugarman S, Norton L, Hudis CA, Dickler MN. Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer. 2009 AACR San Antonio Breast Cancer Symposium. Abstract 4104.
21.	McArthur HL , Lynch C, Morris P, Larson S, Grabski K, Howard J, Patil S, Hudis CA, Dickler MN. Bone scintigraphy (BS) may no longer be relevant in the era of integrated PET/CT for women undergoing evaluation for suspected metastatic breast cancer (MBC). 2009 AACR San Antonio Breast Cancer Symposium. Abstract 5007.
22.	McArthur HL , Mahoney K, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis C. Use of adjuvant trastuzumab with chemotherapy in women with small, node-negative, HER2-positive breast cancers. 2010 ASCO Annual Meeting. Abstract 615.
23.	Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL , Vornik L, Cornelison TL, Hershman DL. Phase 1B randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer. 2010 ASCO Annual Meeting. Abstract TPS142.
24.	Jhaveri KL, Ulaner G, Fazio M, Eaton A, Patil S, Evangelista L, Serna-Tamayo C, McArthur HL , Hudis C, Morris PG. Standardized uptake value (SUV) by positron emission tomography/computed tomography (PET/CT) as a prognostic variable in metastatic breast cancer (MBC). 2011 ASCO Breast Cancer Symposium. Abstract 3.
25.	Crew KD, Lippman S, Hershman DL, Brown P, Greenlee H, Bevers T, Arun B, Hudis C, McArthur HL , Vornik L, Cornelison T. Phase 1B randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer. AACR 2011 International Conference on Frontiers in Cancer Prevention Research. Abstract CN06-02.
26.	Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL , Chang J, Rimawi M, Vornik L, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Biomarker effects of an oral tea extract, Polyphenon E, in women with a history of hormone receptor-negative breast cancer. 2012 Cancer Prev Res. Abstract B65.
27.	Morris PG, Lake D, McArthur HL , Gilewski T, Dang C, Chaim J, Patil S, Lim K, Norton L, Hudis CA, Fornier MN. Phase II trial of dasatinib in combination with weekly paclitaxel for patients with metastatic breast carcinoma. 2012 AACR San Antonio Breast Cancer Symposium. Abstract P5-20-07.

28.	Diab A, McArthur HL , Solomon SB, Sacchini V, Comstock C, Maybody M, Durack JC, Blum B, Yuan J, Patil S, Neville DA, Comen EA, Morris EA, Kotin A, Brogi E, Morrow M, Allison JP, Hudis CA, Norton L, Wolchok JD. A pilot study of single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer scheduled for mastectomy. 2012 AACR San Antonio Breast Cancer Symposium. Abstract 1304.
29.	Morikawa A, Diab A, Patil S, Yang TJ, Hudis CA, McArthur HL , Beal K, Seidman AD. <u>Patient characteristics and outcomes for patients with HER2-overexpressing breast cancer with brain metastases undergoing radiation therapy in the pre- and post adjuvant trastuzumab era.</u> 2013 AACR San Antonio Breast Cancer Symposium. Abstract P6-11-02.
30.	Nemunaitis J, McArthur HL , Hudis C, Reed T, Broder S, Lebel F, Barrett J, Lewis J, Norton L. <u>Regulated intratumoral expression of IL-12 in combination with cytotoxic agents as a strategy for the treatment of metastatic breast cancer.</u> 2013 AACR San Antonio Breast Cancer Symposium. Abstract P5-02-01.
31.	Diab A, Solomon SB, Comstock C, Maybody M, Sacchini V, Durack J, Blum B, Yuan J, Patil S, Neville D, Sung J, Kotin A, Morris E, Brogi E, Morrow M, Wolchok J, Allison J, Hudis C, Norton L, McArthur HL . A pilot study of pre-operative (pre-op), single-dose ipilimumab (ipi) and/or cryoablation (cryo) in women (pts) with early stage/resectable breast cancer (ESBC). 2013 AACR San Antonio Breast Cancer Symposium. Abstract P4-13-01.
32.	Cadoo KA, Morris PG, Lake DE, D'Andrea GM, Dickler MN, Gilewski TA, Dang CT, McArthur HL , Bromberg JF, Goldfarb SB, Modi S, Robson ME, Seidman AD, Sklarin NT, Norton L, Hudis CA, Fournier MN. An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer. 2013 AACR San Antonio Breast Cancer Symposium. Abstract P2-16-12.
33.	Cadoo KA, Morris PG, Patil S, Norton L, Hudis CA, McArthur HL . Impact of adjuvant trastuzumab (T) with chemotherapy on breast cancer specific and cardiac outcomes in older women with small, node-negative HER2-positive breast cancer. 2013 AACR San Antonio Breast Cancer Symposium. Abstract P2-16-11.
34.	Diab A, Solomon SB, Sacchini V, Comstock C, Maybody M, Durack JC, Sung JS, Blum B, Neville DA, Kotin A, Yuan J, Patil S, Morris EA, Brogi E, Morrow M, Wolchok JD, Hudis C, Allison J, Norton L, McArthur HL . A pilot study of preoperative, single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC). 2013 ASCO Annual Meeting. Abstract TPS3120.
35.	Diab A, Solomon SB, Sacchini V, Comstock C, Maybody M, Durack JC, Sung JS, Blum B, Neville DA, Kotin A, Yuan J, Patil S, Morris EA, Brogi E, Morrow M, Wolchok JD, Hudis C, Allison J, Norton L, McArthur HL . A pilot study of preoperative, single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC). 2013 ASCO Breast Cancer Symposium. Abstract 67.
36.	Morikawa A, Diab A, Patil S, Forte V, Blum B, Young RJ, Beal K, Hudis C, Seidman AD, McArthur HL . Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial-Sloan Kettering Cancer Center (MSKCC). 2013 ASCO Breast Cancer Symposium. Abstract 144.
37.	Page D, Wen YH, Dure D, Hudis C, McArthur HL . Prognostic and predictive implications of monosomy 17 in curable HER2-amplified breast cancer. 2014 AACR San Antonio Breast Cancer Symposium. Abstract P1-04-03.
38.	Page D, Yuan J, Diab A, Dong Z, Ginsberg A, Wong P, Emerson R, Redmond D, Blum B, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, Sung J, Brogi E, Morrow M, Solomon S, Sacchini V, Maybody M, Neville D, Robins H, Patil S, Wolchok J, Hudis C, Norton L, Allison J, Sharma P, McArthur HL . <u>Integrated immunologic assessment of tumor</u>

	<u>infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts).</u> 2014 AACR San Antonio Breast Cancer Symposium. Abstract P2-15-01.
39.	Page DB, Diab A, Yuan J, Dong Z, Emerson R, Robins H, Redmond D, Zhao C, Mu Z, Wong P, Solomon SB, Sacchini V, Morrow M, Brogi E, Patil S, Wolchok JD, Hudis CA, Norton L, Allison JP, McArthur HL . T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). 2014 ASCO Annual Meeting. Abstract 3021.
40.	Diab A, McArthur HL , Solomon SB, Sacchini V, Comstock C, Maybody M, Durack JC, Blum B, Yuan J, Patil S, Neville DA, Comen EA, Morris EA, Kotin A, Brogi E, Morrow M, Allison JP, Hudis CA, Norton L, Wolchok JD. A pilot study of preoperative (pre-op), single-dose ipilimumab (ipi) and/or cryoablation (cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). 2014 ASCO Annual Meeting. Abstract 1098.
41.	Page DB, Yuan J, Ginsberg A, Dong Z, Wong P, Emerson R, Sung JS, Comstock C, Solomon SB, Sacchini V, Morrow M, Brogi E, Morris EA, Patil S, Robins H, Wolchok JD, Hudis CA, Norton L, Allison JP, McArthur HL . Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). 2014 ASCO Breast Cancer Symposium. Abstract 64.
42.	Page D, Wen YH, Dure D, Hudis C, Brogi E, McArthur HL . Prognostic and predictive implications of monosomy 17 in curable HER2-amplified breast cancer. 2014 AACR San Antonio Breast Cancer Symposium. Abstract P1-04-03.
43.	Page D, Yuan J, Diab A, Dong Z, Ginsberg A, Wong P, Emerson R, Redmond D, Blum B, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, Sung J, Brogi E, Morrow M, Solomon S, Sacchini V, Maybody M, Neville D, Robins H, Patil S, Wolchok J, Hudis C, Norton L, Allison J, Sharma P, McArthur HL . Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts). 2014 AACR San Antonio Breast Cancer Symposium. Abstract P2-15-01.
44.	McArthur HL , Page D, Proverbs-Singh T, Solomon S, Hudis C, Norton L, Patil S, Barrett JA, Lebel F. <u>Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer.</u> 2015 AACR San Antonio Breast Cancer Symposium. Abstract OT1-01-05.
45.	Riedl C, Pinker K, Ong L, Jochelson MS, Ulaner G, McArthur HL , Dickler MN, Weber W. FDG-PET/CT versus contrast enhanced CT for prediction of progression-free and disease-specific survival in stage IV breast cancer patients. J Clin Oncol, 2015 ASCO Annual Meeting. Abstract 1051.
46.	Page DB, Wen YH, Brogi E, Yuan J, Emerson RO, Patil S, Dang CT, Norton L, Hudis CA, McArthur HL . Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as potential predictive biomarker to neoadjuvant trastuzumab (tras) in HER2-positive (HER2+) breast cancer. 2015 ASCO Annual Meeting. Abstract 609.
47.	McArthur HL , Page DB, Proverbs-Singh TA, Solomon SB, Hudis CA, Norton L, Patil S, Barrett JA, Lebel FM. Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer. 2016 ASCO Annual Meeting. Abstract TPS3097.
48.	McArthur HL , Page DB, Proverbs-Singh TA, Solomon SB, Hudis CA, Norton L, Patil S, Henrich M, Halpenny D, Erinjeri J, Yuan J, Wong P, Jones C, Escudero M, Cai H, Zhou J, Yang Y, Barrett JA, Lebel F. Phase 1b/1l open-label study of Ad-RTS-hIL-12 + veledimex

	gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients. 2016 ESMO Congress. Abstract 280P.
49.	Ho AY, Barker CA, Gucalp A, Lebron-Zapata L, Wen YH, Phung A, Wilgucki M, Henrich M, Arnold B, Patil S, McArthur HL . Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer. 2017 ASCO-SITC Clinical Immuno-Oncology Symposium. Abstract 95.
50.	McArthur HL , Beal K, Halpenny D, Henrich M, Modi S, Barker C, Wong P, Hamilton N, Hudis C, Wolchok J, Norton L. CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM). 2017 AACR Annual Meeting. Abstract 4705.
51.	Schmid P, Cortes J, Bergh J, Denkert C, Verma S, McArthur HL , Zhao J, Aktan G, Dang T, Dent R. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant and pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). 2017 ESMO Congress. Abstract 233TiP.
52.	Sittig M, Mita MM, McArthur HL , Amersi F, Chung A, Giuliano A. Effect of age in young women with stage I-III triple negative breast cancer: A report from the national cancer data base. 2017 ASTRO Annual Meeting. Abstract 2109.
53.	Dent R, Tan T, Kim SB, Traina T, McArthur HL , Im YH, Creel T, Blackwell K. The DORA trial: A non-comparator, randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC). 2017 San Antonio Breast Cancer Symposium. Abstract OT3-04-02.
54.	McArthur HL , Barker CA, Gucalp A, Lebron-Zapata L, Wen YH, Phung Am Wilgucki M, Henrich M, Arnold B, Zhang Z, Ho A. A single-arm, phase II study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC). 2018 ASCO-SITC. Abstract 14.
55.	Lebel, FM, Barrett JA, McArthur HL , Buck JY, Demars N, Mackenna R, Cooper LNJ, Chiocca EA. Demonstration of anti-tumor immunity via intratumoral regulated platform Ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients. 2018 ASCO Annual Meeting. Abstract 3038.
56.	Schmid P, Cortes J, Bergh JC, Pusztai L, Denkert C, Verma S, McArthur HL , Kummel S, Ding Y, Karantza V, Dang T, Dent RA. KEYNOTE-522: phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). 2018 ASCO Annual Meeting. Abstract TPS602.
57.	Page DB, Pucilowska J, Kim IK, Conlin AK, Moxon N, Acheson AK, Kemmer KA, McArthur HL , Mitri ZI, Sanchez K, Lewis SK, Basho RK, Urba WJ, Martel M, Mellinger SL, Perlewitz KS. Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC). 2018 ASCO Annual Meeting. Abstract 1033.
58.	McArthur HL , Barker CA, Gucalp A, Lebron-Zapata L, Wen YH, Kallman C, D'Agnolo A, Rodine M, Arnold B, Zhang Z, Ho AY. A Phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC). 2018 ASCO Annual Meeting. Abstract 1017 (poster discussion).
59.	McArthur HL , Basho R, Shiao SL, Park D, Mita M, Chung A, Arnold B, Martin C, Dang C, Karlan S, Knott S, Giuliano A, Ho A. 271TiP Preoperative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC). 2018 ESMO Congress. Abstract 4382.

60.	Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H , Telli M, Loi S, Cortes J, Schmid P, Harbeck N, Denkert C, Jackisch C, Jia L, Tryfonidis K, Karantza V. KEYNOTE-756: A randomized, double-blind, Phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage ER ⁺ /HER2 ⁻ breast cancer. 2018 AACR San Antonio Breast Cancer Symposium. Abstract OT3-04-03.
61.	Ignatiadis M, McArthur H , Bailey A, Martinez J, De Azambuja E, Metzger O, Lai C, Ponde N, Goulioti T, Daly F, Bouhleb A, Balta V, Van Dooren V, Viale G, Maetens M, DuFrane C, Nguyen Duc A, Winer E, Gelber R, Piccart M. ALEXANDRA/Impassion030: A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer. 2018 AACR San Antonio Breast Cancer Symposium. Abstract OT3-05-02.
62.	McArthur HL , Leal JHS, DiLauro Abaya C, Basho R, Coleman H, Shiao S, Knott S, Tighiouart M, Dadmanesh F, Giuliano A, Verma S. Neoadjuvant Her2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial. 2018 AACR San Antonio Breast Cancer Symposium. Abstract OT3-04-02.
63.	Page DB, Pucilowska J, Bennetts L, Kim I, Sanchez K, Martel M, Conlin A, Moxon N, Mellinger S, Acheson A, Kemmer K, Mitri Z, Vuky J, Ahn J, Abaya C, Manigault T, Basho R, Urba WJ, McArthur HL , Earle A. Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4 ⁺ T-cell count. 2018 AACR San Antonio Breast Cancer Symposium. Abstract P2-09-03.
64.	McArthur HL , Comen EA, Solomon S, Rodine M, DiLauro Abaya C, Leal JHS, Patil S, Norton L. A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard peri-operative care in women with residual triple negative early stage/resectable breast cancer after standard-of-care neoadjuvant chemotherapy. 2018 AACR San Antonio Breast Cancer Symposium. Abstract OT2-06-05.
65.	McArthur HL , Basho R, Shiao SL, Park D, Mita M, Chung A, Arnold B, Martin C, Dang C, Karlan S, Knott S, Giuliano A, Ho A. Preoperative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC). 2018 AACR San Antonio Breast Cancer Symposium. Abstract P2-09-07.
66.	Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H , Telli M, Loi S, Cortes J, Schmid P, Harbeck N, Denkert C, Jackisch C, Jia L, Tryfonidis K, Karantza V. KEYNOTE-756: A randomized, double-blind, Phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage ER ⁺ /HER2 ⁻ breast cancer. 2019 Miami Breast Cancer Conference.
67.	McArthur HL , Ignatiadis M, Guillaume S, Bailey A, Martinez J, Brandão M, Metzger O, Lai C, Fumagalli D, Daly F, Bouhleb A, Karusinova V, Freeman C, Viale G, Honvault V, DuFrane C, Nguyen Duc A, Piccart M, Winer E, Gelber R. ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer. 2019 ASCO Annual Meeting. Abstract TPS598.
68.	Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H , Telli M, Loi S, Cortes J, Schmid P, Harbeck N, Denkert C, Jackisch C, Jia L, Tryfonidis K, Karantza V. KEYNOTE-756: A randomized, double-blind, Phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage ER ⁺ /HER2 ⁻ breast cancer. 2019 ASCO Annual Meeting. Abstract TPS601.

69.	Autio K, Klebanoff C, Schaer D, Kauh J, Slovin S, Blinder V, Comen E, Danila D, Hoffman D, Kang S, McAndrew P, Modi S, Morris M, Rathkopf D, Sanford R, Tate S, Yu D, McArthur H . Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC). 2019 ASCO Annual Meeting. Abstract 2548.
70.	Page D, Chung B, Pucilowska, J, Kim, I, Sanchez, K, Redmond W, Sun Z, Wu Y, Feryn A, Martel M, Abaya C, Wadell D, Mellinger S, Moxon N, Urba W, McAndrew P, El-Masry M, Basho R, Conlin A, McArthur H . Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC). 2019 ASCO Annual Meeting. Abstract 1015 (poster discussion).
71.	Barroso-Sousa R, Trippa L, Lange P, Andrews C, McArthur HL , Haley B, Rugo H, Emens L, Winer E, Mittendorf E, Tolaney S. Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer. 2019 ASCO Annual Meeting. Abstract TPS1115.
72.	Comen E, Bryce Y, Page D, Solomon S, Rodine M, Abaya C, Morris E, Plitas G, El-Tamer M, Gemignani M, Sclafani L, Morrow M, Brogi E, Patil S, Ho T, Wong P, Budhu S, Merghoub T, Norton L, McArthur HL . Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC). 2019 ASCO Annual Meeting. Abstract 592.
73.	Saji S, Ohtani S, Bardia A, Andre F, Cescon DW, McArthur H , Telli M, Loi S, Cortes J, Schmid P, Harbeck N, Denkert C, Jackisch C, Jia L, Hirshfield KM, Karantza V, Cardoso F. KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab + neoadjuvant CT + adjuvant ET for ER+/HER2-BC. 2019 Japanese Society of Medical Oncology JSMO Meeting. Abstract P2-236.
74.	Ignatiadis M, McArthur H , Bailey A, Martinez J, de Azambuja E, Metzger O, Lai C, Franzoi MA, Goulioti T, Daly F, Bouhleb A, Balta V, Maetens M, Viale G, Maetens M, Andre B, DuFrane C, Nguyen Duc A, Gelber R, Piccart M, Winer E. ALEXANDRA/Impassion030: A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer. 2019 ESMO Congress.
75.	Schmid P, Cortes J, Dent R, Pusztai L, McArthur H , Kuemmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Caroso F, Jia L, Karantza V, Zhao J, Aktan G, O'Shaughnessy J. KEYNOTE-522:Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). 2019 ESMO Congress. Abstract 1812.
76.	Cortes J, Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H , Telli M, Loi S, Schmid P, Harbeck N, Denkert C, Jackisch C, Jia L, Hirshfield KM, Karantza V. KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage ER+/HER2-breast cancer. CoBrCA 2019.
77.	McArthur HL , Comen EA, Bryce Y, Solomon SB, Leal JHS, Rodine M, Abaya CD, Patil S, Page DB, Norton L. ; A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy. ESMO 2019. Abstract 1481.

78.	McArthur HL , Leal JHS, Page DB, Bardia A, Spring L, Abaya CD, Basho RK, Ristow L, Coleman H, Shiao S, Knott S, Tighiouart M, Dadmanesh F, Verma S, Giuliano A. Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial. ESMO 2019. Abstract 1479.
79.	Loi S, McArthur H , Harbeck N, Pusztai L, Delaloge S, Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Curigliano G. Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2-primary breast cancer: CheckMate 7FL. SABCS 2019. Abstract OT2-04-03.
80.	McArthur HL , Leal JHS, Page DB, Bardia A, Spring L, Abaya CD, Basho RK, Ristow L, Coleman H, Shiao S, Knott S, Tighiouart M, Dadmanesh F, Verma S, Giuliano A. Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase 2 trial. SABCS 2019. Abstract 890.
81.	McArthur HL , Comen EA, Bryce Y, Solomon SB, Leal JHS, Rodine M, Abaya CD, Patil S, Page DB, Norton L. ; A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy. SABCS 2019. Abstract 896.
82.	McArthur H , Shiao S, Karlan S, Amersi F, Arnold B, Basho R, Burnison M, Chung A, Chung C, Dang C, Giuliano A, Habibi Khameneh N, Knott S, Martin C, McAndrew P, Mita M, Park D, Abaya C, Ho A. Pre-operative pembrolizumab (pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC). SABCS 2019. Abstract 1136.
83.	Cortes J, Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H , Telli M, Loi S, Schmid P, Harbeck N, Denkert C, Jackisch C, Jia L, Hirshfield KM, Karantza V. KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage ER+/HER2-breast cancer. ESMO Asia 2019.
84.	Cortes J, Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H , Telli M, Loi S, Schmid P, Harbeck N, Denkert C, Jackisch C, Jia L, Hirshfield KM, Karantza V. KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage ER+/HER2-breast cancer. ASBS 2020.
85.	Curigliano G, McArthur H , Harbeck N, Pusztai L, Delaloge S, Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Loi S. A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. ESMO Breast Cancer 2020. Abstract 134TiP.
86.	O'Shaughnessy J, Park YH, Ferreira M, Mouret-Reynier M, Im S, Ahn J, Gion M, Hui R, Baron-Hay S, Boileau J, Liu M, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Andersen J, Untch M, Tokar M, Dalenc F, Danso M, Patt D, Kummel S, Denkert C, Pusztai L, Bergh J, McArthur H , Jia L, Aktan G, Zhao J, Karantza V, Dent R, Cortes J, Schmid P. KEYNOTE-522: pathologic complete response in key subgroups of phase 3 study of pembrolizumab versus placebo in early triple-negative breast cancer. 2020 Miami Breast Cancer Conference (MBCC).
87.	Loi S, McArthur H , Harbeck N, Pusztai L, Delaloge S, Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Curigliano G. A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. 2020 ASCO Annual Meeting. Abstract TPS604.

88.	Schmid P, Cortes J, Pusztai L, McArthur H , Kummel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J. KEYNOTE-522: Pembrolizumab for early triple-negative breast cancer. 2020 Society of Surgical Oncology (SSO) International Conference.
89.	Dent R, Cortes J, Pusztai L, McArthur H , Kuemmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Jia L, Jensen E, Karantza V, Aktan G, O'Shaughnessy J, Schmid P. KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC). ESMO Asia Virtual Congress 2020. Abstract 10.
90.	Schiff J, Sittig MP, Cook-Wiens G, Mirhadi AJ, Burnison M, Amersi F, Chung A, Dang C, Giuliano AE, Karlan S, Basho R, El-Masry M, McAndrew P, McArthur HL , Mita M, Park D, Shiao SL. Impact of age in women with stage I-III triple negative breast cancer (TNBC): a national cancer data base (2004-2014 report. American Society for Radiation Oncology (ASTRO) Annual 2020 Virtual Meeting. Abstract 2142.
91.	Lu DJ, Kamrava M, McArthur HL , Reckamp K, Tamarappoo B, Atkins KM. Using natural language processing to identify patients with immune checkpoint inhibitor-associated myocarditis. American Society for Radiation Oncology (ASTRO) Annual 2020 Virtual Meeting. Abstract 3793.
92.	Comeaux J, Lee J, Dondanville D, Culver J, Gorman N, Quinn E, Lerman C, Li M, McArthur H . Risk reducing mastectomies among women with mutations in moderate penetrance breast cancer susceptibility genes. National Society of Genetic Counselors (NSGC) Virtual Annual Conference 2020. Abstract CAN53.
93.	Chun B, Pucilowska J, Conrad V, Schmidt M, Kim I, Fields P, Conlin A, McArthur H , Page D. Impact of chemotherapy (chemo) on t-cell maturation and clonal proliferation in early-stage and metastatic breast cancer. SABCS 2020. Abstract PS17-07.
94.	Mittendorf E, Tolaney S, Wileyto P, DeMeo M, Rugo H, Nanda R, Mayer I, Park B, McArthur H , DeMichelle A. Combination ipatasertib and atezolizumab to prevent recurrence in triple negative breast cancer (TNBC): A phase II single arm. SABCS 2020. Abstract OT-33-01.
95.	McArthur H , Shiao S, Karlan S, Basho R, Amersi F, Arnold B, Burnison M, Chung A, Chung C, Dang C, Giuliano A, Kapoor N, Khameneh N, Knott S, Martin C, McAndrew P, Mita M, Park D, Abaya C, Ho A. Pre-operative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC). SABCS 2020. Abstract PS12-09.
96.	Shigehira S, McArthur H , Michail I, Andrew B, Sarra E, Mariana B, Otto M, Catherine L, Sebastien G, Debora F, Dominique A, Aicha S, Rosa A, Honvault V, Giuseppe V, Dufrane C, Barata T, Winer E, Gelber R, Martine P. ALEXANDRA/Impassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer. ASCO 2021. Abstract TPS597.
97.	Chun B, Pucilowska J, Chang S, Kim I, Nikitin B, Koguchi Y, Redmond W, Barnard B, Rajamanickam V, Polaske N, Fields P, Conrad V, Schmidt M, Urba W, Conlin A, McArthur H , Page D. Effects of chemoimmunotherapy on the peripheral blood: Insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC). SITC 2021. Abstract A103.
98.	Kummel S, Cortes J, Dent R, Pusztai L, McArthur H , Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Ding Y, Tryfonidis K, Aktan G,

	Karantza V, O'Shaughnessy J, Schmid P. Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study. ESSO 2021. Abstract.
99.	Kaufman P, Martin M, Mayer I, Vahdat L, Pernas S, Schmid P, McArthur H , Dent R, Rugo HS, Barrios C, Bobirca A, Ringeisen F, Schmitter D, Cortes J. Balixafortide [a CXCR4 antagonist] + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer: an international, randomized, phase 3 trial [FORTRESS]). SABCS 2021. Abstract PD13-01.
100.	Schmid P, Cortes J, Dent R, Pusztai L, McArthur H , Kümmel S, Bergh J, Denkert C, Hee Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier M-A, Im S-A, Ahn J-H, Gion M, Baron-Hay S, Boileau J-F, Zhu Y, Pan W, Tryfonidis K, Karantza V, O'Shaughnessy J. KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer (TNBC). SABCS 2021 Abstract GS1-01.
101.	Kang I, Deshpande K, Persing S, Yin J, Xiu J, Korn WM, Zeng J, Roussos-Torres ET, Lu J, Spicer D, Sener SF, Tan AR, Sumrall A, Hoon DSB, Ma CX, Anders CK, McArthur HL , Basho R, Lenz H-J, Neman J. Comprehensive characterization of neurotransmitters and neuronal signaling gene alterations in invasive breast cancers. SABCS 2021. Abstract PD6-06.
102.	McArthur HL , Shiao S, Karlan S, Basho R, Amersi F, Burnison M, Mirhadi A, Chung A, Chung CT, Dang C, Richardson H, Giuliano AE, Kapoor N, Larkin B, Godinez H, Dunn SA, Habibi Khameneh N, Knott S, McAndrew P, Mita M, Park DJ, Abaya C, Chen JH, Ly A, Bossuyt V, Ho A. The PEARL trial: Pre-operative pembrolizumab with radiation therapy in early stage triple negative breast cancer. SABCS 2021. Abstract PD10-01.
103.	Takahashi M, Cortes J, Dent R, Pusztai L, McArthur H , Kummel S, Denkert C, Park YH, Im S, Ahn J, Mukai H, Huang C, Chen S, Kim MH, Jia L, Li XT, Tryfonidis K, Karantza V, Iwata H, Schmid P. Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: KEYNOTE-522 Asian subgroup. JSMO 2022. Abstract PS2-3.
104.	Dent R, Cortes J, Pusztai L, McArthur H , Sherko Kummel, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Im S, Ahn J, Mukai H, Huang C, Chen S, Kim MH, Jia L, Li XT, Pan W, Karantza V, Iwata H, O'Shaughnessy J, Schmid P. KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: event-free survival sensitivity and subgroup analyses. APBCS 2022. Abstract GS1-02.
105.	Pusztai L, Schmid P, Cortes J, Dent R, McArthur H , Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Zhu Y, Pan W, Tryfonidis K, Karantza V, O'Shaughnessy J. Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: event-free survival sensitivity and subgroup analyses from KEYNOTE-522. Miami Breast Cancer Conference 2022.

106.	Dent R, Cortes J, Pusztai L, McArthur H , Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Haiderali A, Jia L, Nguyen AM, Pan W, O'Shaughnessy J, Schmid P. HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: results from KEYNOTE-522. ESMO 2022. Abstract 135MO.
------	--

Case Reports

1.	McArthur HL , Dalal BI and Kollmansberger C. Intravascular hemolysis as a complication of Clostridium perfringens sepsis. J Clin Oncol. 2006;24(15):2387-2388.
2.	McArthur HL and Fornier MN. Treatment of a patient with relapsed ErbB2-positive metastatic breast cancer with lapatinib. Case studies in breast cancer 2007;5(10):1-6.

Non-peer reviewed scientific or medical publications/materials in print or other media

1.	McArthur HL and Gill S. Experts on call: Tamoxifen: Suitable for breast cancer prophylaxis in high risk patients? The Canadian Journal of Diagnosis 2006;23(6):33.
2.	McArthur HL and Gill S. Experts on call: Calculating lifetime risk for breast cancer. The Canadian Journal of Diagnosis 2006;23(3):29.
3.	McArthur HL and Fornier MN. Molecular diagnostics for breast cancer. Eur Oncol Disease 2006;2:66-69.
4.	McArthur HL and Kennecke HF. Rationale for extended adjuvant letrozole after five years of tamoxifen in postmenopausal ER+ women with early stage breast cancer. Family Practice Oncology Network Newsletter 2006;5.
5.	McArthur HL and Hudis CA. Update on adjuvant chemotherapy in breast cancer. SABCS 2006: Evolving therapeutic options for patients with early breast cancer. Medscape (http://www.medscape.com), Jan 2007.
6.	McArthur HL and Hudis CA. Adjuvant chemotherapy for early stage breast cancer. US Oncological Disease 2007;2:57-61.
7.	McArthur HL and Hudis CA. The medical treatment of metastatic breast cancer. (http://www.clinicaloncology.com); September 2007.
8.	McArthur HL and Hudis CA. Randomized trial: Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Breast Diseases: A Year Book Quarterly 18(1):101, 2007.
9.	McArthur HL and Hudis CA. Advances in the treatment of early stage breast cancer. ASCO 2008: Breast cancer. Medscape (http://www.medscape.com), July 2008.
10.	McArthur HL and Hudis CA. Adjuvant therapy for HER2-normal early stage breast cancer. SABCS 2007: Adjuvant treatment of breast cancer. Medscape (http://www.medscape.com), Jan 2008.
11.	McArthur HL , Dickler MN and Lipton A. Treatment of HER2-positive/hormone receptor-positive metastatic breast cancer with endocrine therapy plus HER2-targeted therapy. Oncology Consultation. 2008;4(12):1-9.
12.	McArthur HL , Hudis CA. Evaluation and treatment of breast cancer. In Stubblefield M and O'Dell M (ed): cancer rehabilitation, principles and practice. The diagnosis and treatment of breast cancer. Principles and Practice of Cancer Rehabilitation. 2009;181-92.

13.	McArthur HL. Standard chemotherapy options in the adjuvant setting and future directions. In Dang C and Hudis CA (ed): Oncology, “The adjuvant treatment of breast cancer.” 2009;23(suppl 3):7-12.
14.	Morris PG, McArthur HL , Dang CT, and Hudis CA. Selection of appropriate patients for anthracycline therapy. American Society of Clinical Oncology (ASCO) 2009 Annual General Meeting Educational Book.
15.	Murphy C, Hudis CA, McArthur HL. Adjuvant chemotherapy for breast cancer: Updates and new perspectives. In: Tan AR, ed. Emerging Cancer Therapeutics. New York, NY: Demos Medical Publishing; 2011;495-507.
16.	Page DB, McArthur HL. Immunotherapy for breast cancer: Where are we and where are we heading? 2013 Breast Cancer Symposium Proceedings. San Francisco, CA, September 2013.
17.	Page DB, McArthur HL. Immunologic checkpoint blockade strategies in breast cancer. 2014 ASCO Breast Cancer Symposium Daily News. San Francisco, CA, September 2014.
18.	Page DB, Naidoo J, McArthur HL. San Antonio Breast Cancer Symposium 2015: A successful liftoff for breast cancer immunotherapy? Nature Breast Cancer. 2015;15001.
19.	Basho RK, McArthur HL. Advances in the treatment of hormone receptor-positive metastatic breast cancer. Annals of Women’s Health. 2017;1(2):1008.
20.	McArthur H. Management of heterogeneous breast cancers. Audio Digest Oncology 2018;09:15.
21.	McArthur H , Leal J. Immunotherapies move forward in breast cancer. Targeted Oncology. 2018;41:46.
22.	Leal J, Force J, McArthur HL. The role of checkpoint blockade in management of early state breast cancer. Medical Research Archives. 2019;7(4).
23.	McArthur HL. Combining chemotherapy and immunotherapy for the treatment of triple-negative breast cancer. Oncology. 2019;33(4):137-40.
24.	McArthur, H.: Genomics for hormone receptor-positive early state breast cancer. AudioDigest Oncology 2020;11:03.
25.	Kim I, Sanchez K, McArthur H , Page D. Immunotherapy in triple negative breast cancer: present and future. Current Breast Cancer Reports. 2019; 11:259-271.
26.	Chun BM, Page DB, McArthur HL. Combination immunotherapy strategies in metastatic breast cancer. Current Breast Cancer Reports. 2019; 228-240.
27.	Leal J, McArthur H. Breast cancer immunotherapy: from biology to current clinical applications. EMJ. 2020;5(2):113-124.
28.	Ho AY, Tabrizi S, Dunn SA, McArthur HL. Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer. Breast Cancer Res Treat. 2022;191:229-41.
29.	Leal J, Suzuki R, McArthur H. Immunotherapy for the treatment of breast cancer. EMJ 2020 (In Press).